The Review Of
DIABETIC
STUDIES OPEN ACCESS

# Multidisciplinary Dental Hospital Management Of Nasopharyngeal Cancer Patients Undergoing Chemo-Radiotherapy

**Aadl Mohammd Y Sawadi[1],Shaker Mofareh Faqeeh[2],Shadi Abdullah Hamzi[3],Adel Mohammed Jawhali[4],Mohammed Hamoud Muharraq[5],Sultan Ahmad Ali Sayd[6],Waleed mohammed Alaki[7],Riyadh Saleh Hawbani[8],Abdulhadi Ahmed Mashragi[9],Ismail Yahya Gharamah[10],Ahmed Musa Musawa[11]**

*[1,2,4,5,6,7,8,10]Clinical Administration, University dental hospital, college of dentistry, Jazan University*
*[3]College of Dentistry, Jazan University.*
*[9]College of Pharmacy, Jazan University Department of Pharmaceutics*
*[11]University Hospital Medical Stores Department*

**Abstract:**

**Background:** Nasopharyngeal carcinoma (NPC) is a malignancy with a distinct epidemiology, showing a high prevalence in East and Southeast Asia. Its etiology is multifactorial, involving Epstein-Barr virus (EBV) infection, genetic susceptibility, and environmental factors like consumption of preserved foods. The deep anatomical location of the nasopharynx and the frequent presentation at advanced stages complicate management.

**Aim:** This review aims to consolidate current knowledge on the multidisciplinary management of NPC patients undergoing chemo-radiotherapy, encompassing epidemiology, pathophysiology, diagnosis, staging, treatment protocols, and the essential role of integrated healthcare teams.

**Methods:** A comprehensive review of the scientific literature was conducted, synthesizing information on NPC's anatomical basis, histopathological classification (WHO types 1-3), diagnostic evaluation (including endoscopy, CT, MRI, and PET-CT imaging), and evidence-based treatment strategies. The central role of concurrent chemoradiation, primarily with cisplatin-based regimens and intensity-modulated radiation therapy (IMRT), is detailed.

**Results:** Treatment for locoregionally advanced NPC (Stages II-IV) is primarily nonsurgical, relying on concurrent chemoradiation, which significantly improves survival. IMRT allows precise targeting, improving local control while reducing toxicity. Induction or adjuvant chemotherapy is used in advanced cases. Prognosis is stage-dependent, with 5-year survival rates ranging from approximately 82% for Stage I to 49% for Stage IV. Care is complicated by acute and late treatment-related toxicities, including xerostomia, dysphagia, and hearing loss.

**Conclusion:** The management of NPC necessitates a complex, protocol-driven approach centered on chemo-radiotherapy. Optimal patient outcomes are achieved through a coordinated, multidisciplinary team strategy that integrates precise staging, advanced radiation techniques, systemic therapy, and comprehensive supportive care to manage treatment sequelae and ensure long-term surveillance.

**Keywords:** Nasopharyngeal carcinoma, Chemoradiotherapy, Intensity-modulated radiation therapy, Epstein-Barr virus, Multidisciplinary team, Head and neck cancer.

## Introduction:

The pharynx is a musculomembranous tubular conduit that anatomically links the nasal cavities to the larynx and trachea, serving as a critical crossroads for the respiratory and digestive tracts. Its uppermost segment, the nasopharynx, occupies a complex anatomical region positioned posterior to the nasal cavity and superior to the oropharynx. This space is surrounded by several key structural landmarks. Anteriorly, it is bounded by the posterior choanae of the nasal cavity, which constitute the transitional aperture between the nasal passages and the nasopharyngeal chamber. Posteriorly, the nasopharynx is delineated by mucosa that overlies the superior pharyngeal constrictor muscle, providing both structural support and a muscular boundary. Laterally, the region is defined by the fossae of Rosenmuller, the openings of the eustachian (pharyngotympanic) tubes, and the tori tubarius, collectively forming recesses and prominences that are of particular relevance in both normal physiology and pathological processes. Superiorly, the nasopharynx is constrained by the body and clivus of the sphenoid bone, whereas inferiorly it is continuous with, and functionally connected to, the soft palate, which plays an essential role in velopharyngeal closure during swallowing and speech. Malignant neoplasms originating within the nasopharyngeal mucosa are most frequently squamous cell carcinomas. These tumors display biological and clinical characteristics that can be distinct from squamous cell carcinomas arising in other subsites of the head and neck, including differences in etiologic factors, patterns of spread, and response to therapy. The fossa of Rosenmuller, a deep pharyngeal recess located posterolateral to the eustachian tube orifice, is recognized as the most common primary site for nasopharyngeal carcinoma, accounting for approximately half of all cases arising in this anatomic region [1]. The predilection of nasopharyngeal carcinoma for this anatomically concealed recess has important implications for early detection, as lesions in this area may remain clinically silent until they reach an advanced stage [1].

Nasopharyngeal carcinoma is characterized by striking geographic and ethnic variations in incidence, reflecting a complex interplay between genetic predisposition, environmental exposures, and infectious agents. In particular, populations in East and Southeast Asia, with China as the most prominent example, exhibit a markedly elevated incidence of this malignancy compared with most other regions of the world [2]. Notably, Chinese ancestry itself has been identified as an independent risk factor, even among individuals who reside outside high-incidence regions, suggesting that underlying genetic or heritable factors contribute significantly to disease susceptibility [2]. In addition, an increased incidence of nasopharyngeal carcinoma has been observed among individuals of Native Alaskan ancestry, further emphasizing the importance of ethnicity and genetic background in disease risk [3]. These epidemiologic patterns have prompted extensive research into the molecular and environmental determinants of nasopharyngeal carcinogenesis. In areas where nasopharyngeal carcinoma is highly prevalent, the majority of cases are etiologically associated with infection by Epstein-Barr virus (EBV). EBV is a ubiquitous herpesvirus that infects a substantial proportion of the global population, often in childhood, typically establishing a latent and lifelong infection. This near-universal prevalence poses a major challenge to fully delineating the specific viral and host mechanisms that drive malignant transformation in only a small subset of infected individuals [4]. Nonetheless, several EBV-encoded oncogenic proteins and latent gene products, including latent membrane proteins LMP-1 and LMP-2, as well as the Epstein-Barr nuclear antigen EBNA1, have been demonstrated to play crucial roles in cellular transformation, immune evasion, and tumor progression in nasopharyngeal carcinoma [5]. These viral factors modulate multiple signaling pathways and contribute to the characteristic molecular profile of EBV-associated tumors. Although nasopharyngeal carcinomas related to human papillomavirus (HPV) have been reported, particularly in some low-incidence regions, a definitive and consistent causal association between HPV and nasopharyngeal carcinoma has not been established, and EBV remains the predominant viral agent implicated in its pathogenesis [1][2][3].

**Fig. 1: Nasopharyngeal Carcinoma.**




The clinical course and therapeutic responsiveness of nasopharyngeal carcinoma are strongly influenced by its histopathological subtype. To standardize classification and facilitate prognostication and treatment planning, the World Health Organization (WHO) categorizes nasopharyngeal carcinoma into three principal histologic types. Type 1 tumors are keratinizing squamous cell carcinomas, which tend to resemble conventional squamous carcinomas seen in other head and neck subsites. These tumors are associated with EBV infection in approximately 70% to 80% of cases [6]. Type 2 carcinomas are differentiated nonkeratinizing tumors, and type 3 carcinomas are undifferentiated nonkeratinizing nasopharyngeal carcinomas; the latter represents the most frequently encountered histologic subtype worldwide [7]. Types 2 and 3 are generally more radiosensitive and chemosensitive than keratinizing tumors and thus often demonstrate better treatment responses and clinical outcomes under contemporary therapeutic protocols [7]. Almost all cases of type 2 and type 3 nasopharyngeal carcinoma are closely linked to EBV infection and are predominantly observed in regions where EBV is endemic, reinforcing the central etiologic role of this virus in nonkeratinizing disease. More recently, nasopharyngeal carcinoma with basaloid features has been recognized as a rare, distinct histologic variant, notable for its aggressive clinical behavior and poorer prognosis [8]. The selection of treatment modalities for nasopharyngeal carcinoma is guided primarily by tumor stage, histologic subtype, and overall patient condition. Owing to the deep-seated location of the nasopharynx, its proximity to critical neurovascular structures, and the frequent presence of submucosal and skull base extension at diagnosis, surgical resection is often technically challenging and associated with significant morbidity. As a result, management is typically nonsurgical, with radiation therapy serving as the cornerstone of treatment. For early-stage disease, including stage I and stage II tumors, high-dose external beam radiation therapy alone is often sufficient to achieve locoregional control and long-term survival. In contrast, for more advanced tumors, classified as stage III or stage IV, concurrent chemoradiotherapy is generally recommended, with systemic chemotherapy added to improve radiosensitivity, enhance locoregional control, and reduce the risk of distant metastasis. In recent years, there has been increasing interest in the utilization of genetic and molecular markers, including viral-associated surface proteins and EBV-related antigens, as potential targets for immunotherapeutic strategies and precision oncology approaches in nasopharyngeal carcinoma [9]. Such innovations may further refine risk stratification and enable more individualized treatment algorithms in the future.

Over the past decade, significant progress has been made in the diagnosis and management of nasopharyngeal carcinoma, resulting in notable reductions in disease-related mortality [10][11][12]. Improvements in imaging modalities, enhanced understanding of tumor biology, more widespread use of combined modality therapy, and the development of sophisticated radiation techniques such as intensity-modulated radiotherapy have collectively contributed to better locoregional control and survival outcomes. Additionally, increased awareness in high-risk populations and efforts toward earlier detection have facilitated the diagnosis of disease at more curable stages. These advances underscore the critical importance of ongoing clinical and translational research aimed at refining therapeutic regimens, optimizing long-term functional outcomes, and further reducing treatment-related toxicities. Continuous innovation in the fields of virology, immuno-oncology, radiotherapy, and supportive care remains essential to improving the prognosis and quality of life of patients affected by nasopharyngeal carcinoma.

**Etiology**

The etiology of nasopharyngeal carcinoma is multifactorial and remains only partially elucidated, reflecting a complex interplay between genetic susceptibility, environmental exposures, and viral oncogenesis. Current evidence supports the notion that no single causative factor is sufficient in isolation; rather, carcinogenesis arises from the convergence of inherited genetic predisposition, lifestyle or dietary influences, and infection with oncogenic viruses such as Epstein-Barr virus (EBV). The relative contribution of each of these elements appears to vary across geographic regions and ethnic populations, which likely accounts for the marked epidemiologic heterogeneity observed in nasopharyngeal carcinoma incidence worldwide. In regions where EBV is not endemic or is not strongly implicated in tumorigenesis, including much of the United States and other low-incidence Western countries, traditional head and neck cancer risk factors such as tobacco smoking and alcohol consumption have been identified as significant contributors to nasopharyngeal carcinoma risk [13]. These exogenous exposures may drive carcinogenesis through the induction of chronic mucosal irritation, DNA damage, and accumulation of somatic mutations. By contrast, in EBV-endemic regions, such as Southern China and parts of Southeast Asia, this association with smoking and alcohol is much weaker or absent, suggesting that EBV-related mechanisms overshadow the carcinogenic impact of these lifestyle factors in those populations [13]. This epidemiologic divergence is mirrored in the World Health Organization (WHO) histologic classification of nasopharyngeal carcinoma. WHO type 1 tumors, which are keratinizing squamous cell carcinomas, show more etiologic heterogeneity and are frequently unrelated to EBV infection, aligning more closely with the risk profile of conventional squamous cell carcinomas of other head and neck subsites. In contrast, WHO type 2 (differentiated nonkeratinizing) and type 3 (undifferentiated nonkeratinizing) nasopharyngeal carcinomas demonstrate a consistent and strong association with EBV, and EBV infection is considered a central and defining etiologic factor for these subtypes [14].

Ethnicity and genetic background represent additional key determinants of nasopharyngeal carcinoma susceptibility. Asian ancestry, particularly Southern Chinese ancestry, has long been recognized as a major independent risk factor, even among individuals who have migrated away from high-incidence regions and reside in countries with otherwise low background rates of the disease [15]. This observation strongly implicates inherited or ancestral genetic factors in predisposing certain populations to nasopharyngeal tumorigenesis. A similar pattern is observed in individuals of Native Alaskan ancestry, who also display a disproportionate risk of developing nasopharyngeal carcinoma. Mitochondrial DNA analyses, particularly of the D4h haplogroup, have revealed common ancestral genetic links between Native Alaskan populations and East Asian groups, providing a plausible explanation for the shared elevated risk and suggesting that these populations may harbor overlapping genetic susceptibility loci [16]. Dietary exposures have also been implicated in the pathogenesis of nasopharyngeal carcinoma, particularly in endemic regions. Diets rich in preserved foods, especially salted and preserved fish, have been extensively studied as potential risk factors [17]. These preserved products may contain high levels of nitrosamines and other carcinogenic compounds formed during preservation and fermentation processes. Chronic ingestion of such foods during early life has been hypothesized to contribute to mucosal DNA damage, facilitate EBV-driven oncogenesis, or act

synergistically with latent viral infection and genetic predisposition to promote malignant transformation [17]. The timing and duration of exposure may be critical, with some studies suggesting that childhood and adolescent dietary patterns are particularly relevant in shaping long-term cancer risk.

Further support for the role of hereditary and shared environmental factors comes from epidemiologic studies that document familial aggregation of nasopharyngeal carcinoma in both endemic and nonendemic regions [18][19]. The occurrence of family clusters, often involving multiple affected first-degree relatives, indicates that common genetic variants, shared environmental exposures, or a combination of both may underlie this observed familial risk. These familial patterns have stimulated ongoing efforts to identify specific genetic polymorphisms and susceptibility genes, such as those within the HLA region and other immune-regulatory loci, that may modulate host response to EBV and influence carcinogenic pathways. In many high-incidence regions, circulating EBV DNA has gained prominence not only as a marker of etiologic involvement but also as a useful tool for disease screening, risk stratification, and post-treatment surveillance. Quantitative assays for plasma EBV DNA are increasingly utilized to detect subclinical or early-stage disease in high-risk populations, with elevated levels correlating with tumor burden and advanced stage at diagnosis [20]. High pretreatment EBV DNA levels have been consistently associated with poorer treatment response, higher rates of distant metastasis, and increased disease-related mortality, underscoring the prognostic relevance of this biomarker [20]. Although the prognostic significance of EBV DNA titers has not yet been comprehensively characterized in all settings, persistently elevated or rising EBV DNA levels following completion of therapy have been described as a powerful adverse prognostic factor for overall survival and disease-free survival [21][22]. This persistent viremia may reflect minimal residual disease, occult micrometastases, or treatment-resistant tumor clones, and thus provides an important window into the biological behavior of the malignancy. Collectively, these findings highlight nasopharyngeal carcinoma as a paradigmatic example of a cancer in which viral oncogenesis, inherited genetic predisposition, and environmental and lifestyle factors are intimately intertwined. The complexity of its etiology continues to drive research aimed at disentangling these interactions, with the ultimate goal of improving primary prevention strategies, refining risk prediction models, and optimizing early detection protocols in vulnerable populations [21][22].

## Epidemiology

The epidemiology of nasopharyngeal carcinoma is distinguished by pronounced geographic, ethnic, and age-related variations, reflecting the complex interplay of viral, genetic, and environmental factors that influence its distribution. In regions classified as nonendemic—particularly the Americas and Europe—the disease remains rare, with reported incidence rates of fewer than one case per 100,000 individuals [23]. This low prevalence contrasts sharply with the situation in endemic areas, where rates rise dramatically. The highest incidence has been documented in certain regions of Southern China, especially Guangdong and Guangxi provinces, where nasopharyngeal carcinoma may reach up to 21 cases per 100,000 people and accounts for approximately 18% of all malignancies diagnosed in these populations [24]. These striking differences underscore the central role of ancestry, environmental exposures, and the high prevalence of Epstein-Barr virus (EBV) infection in influencing disease risk. In much of Asia, where endemic nasopharyngeal carcinoma is most prevalent, the disease typically presents in middle age. Patients commonly seek medical attention during the fourth to sixth decades of life, a pattern consistent across numerous epidemiologic studies [25]. This age distribution suggests that carcinogenesis may progress over many years, possibly beginning with early-life EBV infection, followed by the accumulation of genetic and environmental cofactors that ultimately drive malignant transformation. In contrast, in many African regions where EBV infection is widespread, nasopharyngeal carcinoma often affects a much younger population. A substantial proportion of cases in Africa occur in children, highlighting yet another distinct epidemiologic pattern associated with endemic EBV exposure, genetic susceptibility, and possibly unique environmental influences [26][27].

Regions outside endemic zones, including most of North America and Europe, demonstrate a bimodal age distribution of nasopharyngeal carcinoma. The first peak occurs during late adolescence, while the second peak emerges in older adulthood, typically between the sixth and seventh decades of life [28]. This dual-age pattern suggests that different etiologic mechanisms may be at play in younger versus older patients, possibly reflecting varying contributions of viral, environmental, and hereditary factors. Gender disparities are another salient epidemiologic feature. Across multiple populations, nasopharyngeal carcinoma occurs more frequently in males than in females. Men are estimated to have a 2.75-fold higher risk of developing the disease and a 3.25-fold greater risk of nasopharyngeal carcinoma–specific mortality compared with women [29]. While the underlying reasons for these differences are not definitively established, lifestyle behaviors such as tobacco use, which traditionally differ between genders in many endemic regions, may contribute to the observed gender gap. For example, in China—where much of the epidemiologic data originates—men smoke at significantly higher rates than women, which may partially explain their elevated risk [29]. However, some studies indicate that this gender disparity diminishes with age. In one large Chinese cohort, the incidence and mortality among individuals older than 55 years were nearly equivalent between the sexes, suggesting that risk factors other than tobacco use may predominate later in life [30]. Overall, the epidemiologic profile of nasopharyngeal carcinoma reflects a cancer deeply shaped by geography, ethnicity, age, and gender. Its uneven global distribution and demographic variations provide important insights into the underlying mechanisms of disease and highlight the need for regionally tailored prevention, screening, and treatment strategies [30].

**Pathophysiology**

Nasopharyngeal carcinoma represents a biologically distinct malignancy within the spectrum of head and neck cancers, characterized by a unique interplay between viral oncogenesis, host genetic susceptibility, and environmental cofactors. Unlike other head and neck squamous cell carcinomas, which are principally related to tobacco and alcohol exposure, nasopharyngeal carcinoma is most strongly associated with Epstein-Barr virus (EBV), and its pathophysiology has been extensively studied through this lens. The predominance of EBV-related disease has driven substantial research into the viral gene products and host determinants that facilitate malignant transformation, illustrating a multistep oncogenic process deeply rooted in the host–virus relationship [31]. In areas where nasopharyngeal carcinoma is endemic, a majority of tumor cells—and even premalignant epithelial lesions—contain EBV DNA. This near-universal presence of viral genetic material reinforces a strong etiologic association and supports the concept that EBV infection is not a secondary event but rather an early and integral component of carcinogenesis. The persistence of EBV in the nasopharyngeal epithelium establishes a latent infection that contributes to dysregulation of normal cellular processes, initiating a cascade of events that ultimately promote malignant transformation. Viral latency allows EBV to evade immune detection and maintain long-term residence within epithelial cells, providing an opportunity for oncogenic gene products to exert their effects on host cellular pathways [31].

Host genetic susceptibility plays an equally crucial role in determining which individuals progress from latent infection to malignancy. Numerous studies have demonstrated a strong correlation between nasopharyngeal carcinoma and specific human leukocyte antigen (HLA) variants. These HLA mutations, particularly those affecting antigen presentation, may impair immune recognition of EBV-infected cells, thereby enabling viral persistence and enhancing susceptibility to malignant transformation [32]. Such mutations are notably more frequent among individuals of Chinese and Southeast Asian ancestry, offering a molecular explanation for the marked geographic and ethnic disparities in incidence. Among the host genetic determinants, polymorphisms in major histocompatibility complex (MHC) class I genes have emerged as some of the most potent risk factors for nasopharyngeal carcinoma development, underscoring the central role of immune modulation in disease pathophysiology [33]. The prevailing model of EBV-related tumorigenesis proposes that nasopharyngeal carcinoma arises from the clonal expansion of a single progenitor epithelial cell that has become latently infected with EBV. This clonal origin is consistent with EBV's established role in other malignancies such as Burkitt lymphoma and Hodgkin lymphoma.

Following initial infection, the virus enters a restricted latency program, expressing a limited set of genes that provide survival signals to the host cell while minimizing immune detection. Over time, a sequence of genetic abnormalities and epigenetic alterations accumulates, driven in part by the viral genome's interaction with host cellular machinery [34].

Among the EBV gene products implicated in oncogenesis, the latent nuclear antigens EBNA1, EBER1, and EBER2 have drawn significant attention. EBNA1 is essential for maintenance and replication of the viral episome within the host nucleus and contributes to genomic instability and disruption of apoptotic pathways [35][36]. The EBV-encoded small RNAs (EBERs) further enhance tumor cell survival by modulating immune responses and promoting a microenvironment conducive to malignant progression. However, the most prominent oncogenic driver identified in nasopharyngeal carcinoma is latent membrane protein 1 (LMP1). LMP1 functions as a constitutively active mimic of CD40, a receptor involved in immune signaling, and therefore exerts powerful effects on multiple intracellular pathways. It activates the NF-κB, MAPK, PI3K, and JNK/AP-1 pathways, all of which are pivotal in regulating cell proliferation, survival, and resistance to apoptosis [37][38]. Through these mechanisms, LMP1 endows infected cells with a proliferative advantage, promotes genomic instability, enhances metastatic potential, and interferes with normal cell-cycle regulation. The cumulative effect of these signaling alterations supports the development of a microenvironment in which malignant transformation is increasingly likely. In summary, the pathophysiology of nasopharyngeal carcinoma reflects a sophisticated interaction between EBV-driven oncogenic processes, host immunogenetic susceptibility, and environmental influences. The disease arises through a stepwise progression involving latent viral infection, immune evasion, genetic alterations, and activation of oncogenic pathways. Continued research into these mechanisms is essential for the development of targeted therapies and for improving early detection and prevention strategies in high-risk populations [35][36].

**Fig. 2: Pathophysiology of nasopharyngeal cancer.**




## Histopathology

Nasopharyngeal carcinoma is characterized by a distinct and well-defined histopathological spectrum that underpins its clinical behavior and guides diagnostic and therapeutic decision-making. The World Health Organization (WHO) classifies nasopharyngeal carcinoma into three principal histologic subtypes on the basis of microscopic architecture and cytologic features: keratinizing squamous cell carcinoma (type 1), nonkeratinizing differentiated carcinoma (type 2), and nonkeratinizing undifferentiated carcinoma (type 3) [39]. Although these categories share a common anatomic origin, they differ substantially in morphology, association with Epstein-Barr virus (EBV), and response to therapy, making accurate histologic classification essential in clinical practice. Type 1 nasopharyngeal carcinoma, the keratinizing subtype, is histologically indistinguishable from keratinizing squamous cell carcinoma occurring at other mucosal sites within the upper aerodigestive tract. On light microscopy, these tumors demonstrate obvious squamous differentiation, with tumor cells forming nests, sheets, or islands composed of polygonal cells possessing abundant eosinophilic cytoplasm. Prominent intercellular bridges are a characteristic feature, reflecting well-formed desmosomal junctions. Keratinization is variably present, often manifested as individual cell keratinization and the formation of keratin pearls—concentric lamellated accumulations of keratin situated within tumor nests. On this basis, type 1 tumors can be graded as well, moderately, or poorly differentiated, depending on the extent and uniformity of keratinization and the degree of cytologic atypia [39]. This grading parallels that used for conventional squamous cell carcinoma in other head and neck locations. Type 2 nasopharyngeal carcinoma, the nonkeratinizing differentiated subtype, displays a quite different histologic profile. The neoplastic epithelium typically grows in anastomosing cords, trabeculae, or nests of tumor cells that are interconnected in a cohesive pattern. The cells show relatively well-defined borders but minimal or absent keratin production, and keratin pearls are generally lacking. Intercellular bridges may be present but are often subtler than in keratinizing tumors and may be focal or inconsistent. Cytologically, the tumor cells frequently exhibit vesicular nuclei and prominent nucleoli, with moderate amounts of cytoplasm. In some cases, the architecture and cytologic appearance can bear resemblance to urothelial carcinoma, particularly when there is a nested or trabecular pattern. The stromal response in type 2 tumors is also characteristic: a desmoplastic, fibrotic reaction is typically absent, in contrast to what may be observed in some other squamous carcinomas. Instead, the supporting stroma commonly contains a dense, nonneoplastic lymphoplasmacytic infiltrate, reflecting the intimate interplay between the tumor and host immune response [39].

An important feature of nonkeratinizing nasopharyngeal carcinoma is the potential for intra-tumoral heterogeneity in the degree of differentiation. Within a single neoplasm, foci that resemble differentiated nonkeratinizing carcinoma (type 2) may coexist with areas that more closely resemble undifferentiated carcinoma (type 3). In such cases, classification is based on the dominant histologic component, which is the pattern occupying the greater proportion of the tumor. The subdivision of nonkeratinizing carcinoma into differentiated and undifferentiated categories is considered optional from a prognostic standpoint, as current evidence indicates that this distinction does not confer major differences in clinical outcome [39]. Type 3 nasopharyngeal carcinoma, the nonkeratinizing undifferentiated subtype, is the most characteristic and frequently encountered histologic form of the disease in endemic regions. It exhibits one of two predominant histologic patterns on hematoxylin and eosin (H&E) staining, known as the Regaud and Schmincke patterns, although these patterns do not appear to be associated with differences in prognosis [40]. In the Regaud pattern, the tumor is composed of large, cohesive sheets or nests of malignant epithelial cells with indistinct cell borders, creating a syncytial appearance. The cells often appear to merge into one another, and the cytoplasm of adjacent cells tends to blend, making individual cell outlines difficult to discern. By contrast, the Schmincke pattern is characterized by a more diffuse, noncohesive growth, in which tumor cells are dispersed within a dense background of inflammatory cells, sometimes closely mimicking the microscopic appearance of non-Hodgkin lymphoma. In both patterns, the neoplastic cells typically exhibit round to oval nuclei with vesicular chromatin and prominent, centrally or eccentrically placed nucleoli. Across type 3 tumors, keratinization is absent, and no keratin pearls are seen. Mitoses are frequently encountered and may be numerous, reflecting the high proliferative activity of this subtype, and apoptotic bodies are commonly observed. Despite the high turnover, overt geographic necrosis is relatively

uncommon. A striking and consistent feature is the presence of a prominent nonneoplastic lymphoplasmacytic infiltrate in the surrounding stroma. This inflammatory background, dominated by T lymphocytes and plasma cells, is so characteristic that type 3 nasopharyngeal carcinoma has historically been termed "lymphoepithelioma." This admixture of malignant epithelial cells and reactive lymphoid elements can create diagnostic challenges, particularly on small biopsies, where the lesion may be mistaken for a lymphoid neoplasm without careful immunohistochemical evaluation [39].

Immunohistochemistry plays an indispensable role in confirming the epithelial nature of the tumor, distinguishing nasopharyngeal carcinoma from morphologic mimics, and supporting the diagnosis of EBV-associated disease. Tumor cells in nasopharyngeal carcinoma typically show strong positivity for cytokeratin-based epithelial markers. High molecular weight keratins and pancytokeratin reliably stain the neoplastic cells, confirming their epithelial origin [41]. Nuclear expression of p63 and p40, transcription factors associated with squamous differentiation and basal epithelial cells, is also commonly observed, further supporting a diagnosis within the spectrum of squamous or squamoid carcinoma [41]. Expression of EBV latent membrane protein (LMP) is a key feature in many cases, particularly in nonkeratinizing carcinomas, and its detection underscores the etiologic role of EBV in the pathogenesis of these tumors. Equally important is the negative immunophenotypic profile for markers that would suggest alternative lineages. Nasopharyngeal carcinoma cells are negative for CK20, which is more typical of colorectal and some urothelial carcinomas, and they do not express leukocyte common antigen CD45, which is characteristic of lymphoid malignancies [41]. Neural and melanocytic markers such as S100, HMB45, and MelanA are also absent, helping exclude melanoma and peripheral nerve sheath tumors. Similarly, markers of skeletal muscle differentiation, including desmin, myoglobin, and myogenin, are negative, allowing differentiation from rhabdomyosarcoma and related sarcomas. CK7 is generally negative in nasopharyngeal carcinoma, although occasional cases may show focal or partial positivity, so its expression must be interpreted with caution and in the context of a broader immunohistochemical panel [41].

Beyond protein expression, direct detection of EBV genetic material represents a critical adjunct in the histopathologic evaluation of nasopharyngeal carcinoma. EBV DNA can be identified in tumor tissue using molecular techniques such as polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH), and it is detected in approximately 75% to 100% of nasopharyngeal carcinoma cases [42]. This high detection rate highlights the strong association between EBV and the disease, particularly in nonkeratinizing subtypes, and supports the routine use of EBV testing as part of the diagnostic workup. The demonstration of EBV within tumor cells not only reinforces the diagnosis in morphologically ambiguous cases but also has implications for prognostication and may increasingly inform therapeutic strategies that target viral or virus-induced pathways. Taken together, the histopathologic and immunophenotypic features of nasopharyngeal carcinoma define a distinctive entity among head and neck malignancies. The integration of conventional microscopy, immunohistochemistry, and EBV-specific molecular testing allows for precise classification into WHO subtypes, facilitates distinction from histologic mimics, and provides a robust framework for understanding the underlying biology of this EBV-associated cancer [41].

**History and Physical**

The clinical presentation of nasopharyngeal carcinoma is closely linked to the stage of disease at the time of diagnosis. Unfortunately, the majority of patients present with advanced disease, and a palpable cervical lymph node metastasis is often the initial and most prominent clinical finding [43]. A painless, solitary, and incidentally discovered neck mass is a common early manifestation not only of nasopharyngeal carcinoma but also of many head and neck malignancies. Clinically, any new neck mass in an adult that persists for two weeks must be considered malignant until proven otherwise, prompting thorough and timely evaluation. A detailed history should include information regarding the onset of the mass, how it was first detected—whether by the patient or a healthcare provider—and any preceding upper respiratory tract infection, dental infection, or inflammatory process that might obscure or complicate the diagnostic picture. It is also important to inquire about whether the mass has changed in size, whether other neck masses have

been noted, and whether symptoms fluctuate over time. In addition to the presence of a neck mass, patients may exhibit a broad spectrum of associated symptoms that reflect local invasion or regional extension of the tumor. Potential symptoms include hoarseness or other voice changes, dysphagia or odynophagia, and referred otalgia, which is frequently observed due to the shared sensory innervation of the nasopharynx and ear via the glossopharyngeal nerve. Obstructive symptoms such as unilateral or bilateral nasal obstruction, recurrent or persistent epistaxis, and postnasal bleeding may suggest tumor involvement of the nasal cavity or posterior choanae. Hemoptysis and hematemesis, although less common, may also occur. Visual disturbances, including diplopia or blurred vision, along with chronic headaches or facial pain, can signal skull base erosion or cranial nerve involvement. Persistent rhinorrhea, particularly in the absence of infection, may indicate obstructive dysfunction of the nasopharynx or eustachian tube [43].

A comprehensive social history is essential in assessing risk factors and guiding clinical suspicion. Inquiry into tobacco and alcohol use remains important, even though these exposures play a lesser etiologic role in EBV-endemic regions. Prolonged sun exposure, whether occupational or recreational, should be documented, along with sunscreen use history, as ultraviolet exposure may reflect broader patterns of environmental risk behavior. Occupational exposures to chemicals, dust, or fumes should also be reviewed. Given the strong ethnic and familial associations with nasopharyngeal carcinoma, obtaining a detailed family history and documenting ancestry—particularly Asian or Southeast Asian heritage—is crucial. A past medical history that includes prior head and neck cancers, dermatologic malignancies, or any condition resulting in immunosuppression may further elevate suspicion for malignant disease. The physical examination of patients with suspected or confirmed nasopharyngeal carcinoma must be meticulous and comprehensive. Examination of the scalp, face, and neck should include inspection and palpation to identify any cutaneous lesions or scars that might represent previously excised malignant or premalignant conditions. Palpation of the cervical lymph nodes is particularly important, as cervical adenopathy is the most common physical finding at presentation. The clinician should note the number, size, location, mobility, and consistency of any palpable nodes. Thyroid nodules and other neck masses should also be documented. The presence of stridor or persistent hoarseness may indicate airway compromise or laryngeal involvement. Otologic evaluation plays a critical role. Special attention should be given to the middle ear, as unilateral middle ear effusion in an adult is a classic red flag for possible nasopharyngeal obstruction caused by tumor involving the eustachian tube. Anterior rhinoscopy allows visualization of the nasal passages and may reveal mass lesions, mucosal abnormalities, or active bleeding. The examination should be repeated after the application of a topical decongestant to improve visualization of deeper structures. Nasal endoscopy is indispensable for thorough inspection of the nasopharynx. While minor amounts of residual adenoid tissue can persist in adulthood, prominent or asymmetric adenoidal tissue in an adult is concerning and warrants biopsy [43].

Examination of the oral cavity and oropharynx should assess mucosal integrity, dentition, and the presence of suspicious lesions. Palpation of the tongue, floor of the mouth, and tonsillar pillars should be performed to identify submucosal masses. Flexible fiberoptic laryngoscopy is necessary to evaluate regions not easily visualized on routine examination, including the base of the tongue, vallecula, epiglottis, and hypopharynx. A thorough cranial nerve examination is mandatory, as nasopharyngeal carcinoma frequently involves the skull base and can affect cranial nerves II through XII. Identification of asymmetries, sensory deficits, diplopia, facial weakness, or impaired gag reflex may provide key diagnostic clues and assist in staging. Taken together, the history and physical examination form the cornerstone of clinical evaluation in nasopharyngeal carcinoma, enabling early suspicion, guiding diagnostic imaging and biopsy, and facilitating prompt and appropriate management in a disease that often presents late in its course [43].

**Evaluation**

The evaluation of suspected nasopharyngeal carcinoma begins with a meticulous history and comprehensive physical examination of the head and neck, as these foundational steps direct all subsequent diagnostic measures. The clinician must approach any suspicious mass identified within the oral cavity, oropharynx, hypopharynx, or thyroid gland with a high index of suspicion. In such circumstances, cross-

sectional imaging is warranted, and a computed tomography (CT) scan of the neck with intravenous (IV) contrast is typically the initial study of choice. CT imaging provides rapid and detailed information about lesion location, size, and potential involvement of adjacent structures, thereby helping to determine the urgency and direction of further evaluation. The selection of advanced imaging for a suspected nasopharyngeal mass, however, has traditionally been a subject of debate. Historically, CT with IV contrast has served as the preferred imaging modality for initial staging of nasopharyngeal carcinoma. CT is particularly effective for assessing erosion or invasion of bony structures—an important consideration given the tumor's proximity to the skull base—and offers valuable visualization of cervical lymph node basins, which play a critical role in staging and prognostication. Moreover, CT scans are often required for radiation therapy planning because of their ability to provide precise anatomical detail useful for designing radiation fields [44]. Yet despite these advantages, CT is less accurate in delineating the full extent of soft tissue involvement. Its spatial resolution may also be insufficient for detecting very small or submucosal tumors, prompting reliance on other imaging modalities such as magnetic resonance imaging (MRI) or positron emission tomography with CT (PET-CT) in certain clinical contexts [45].

Practical considerations also influence the preference for CT as an initial diagnostic tool. CT is more frequently available, typically less expensive, and may be mandated as the first-line study for insurance approval. Additionally, CT is the modality of choice in patients who cannot undergo an MRI due to the presence of implanted metal devices, pacemakers, or severe claustrophobia. When CT is performed to evaluate suspected nasopharyngeal carcinoma, obtaining thin-slice (1 to 2 mm) axial images through the nasopharynx is vital. These fine-cut images optimize visualization of the primary tumor and allow assessment of the skull base foramina, which is critical for detecting perineural spread or early skull base invasion [46]. MRI of the face and neck remains the superior imaging modality for accurately evaluating the primary tumor and determining the T stage. Its superior soft-tissue contrast allows enhanced visualization of tumor boundaries, muscular infiltration, parapharyngeal space involvement, and skull base extension. MRI also excels at identifying subclinical primary tumors that may be undetectable on CT or nasal endoscopy, making it invaluable when CT findings are inconclusive or when endoscopic exams are limited [47]. Although CT is traditionally preferred for evaluating cervical lymph nodes, MRI provides comparable diagnostic accuracy and is considered an acceptable alternative for nodal assessment [48]. PET-CT plays an equally important role, particularly in evaluating distant metastasis—the M stage. Nasopharyngeal carcinoma has a well-recognized propensity to metastasize, commonly to bone, lung, and liver. PET-CT offers a whole-body functional overview, enabling identification of occult metastases and subclinical nodal disease. For this reason, PET-CT is strongly recommended in the staging process, particularly for patients with advanced disease or equivocal findings on anatomic imaging [45][46][47].

**Fig. 3: Diagnosis of nasopharyngeal cancer.**



Establishing a histologic diagnosis is indispensable and must be achieved before finalizing staging or initiating therapy. Biopsy is most effectively performed via endoscopic guidance, allowing direct visualization of the mass and targeted tissue sampling under local or general anesthesia. When the primary tumor is not clearly visible or accessible, fine needle aspiration (FNA) of a metastatic cervical lymph node can provide critical diagnostic information. Cytologic analysis combined with EBV testing can confirm the presence of metastatic nasopharyngeal carcinoma. A positive EBV result within a metastatic lymph node strongly supports the diagnosis of an occult nasopharyngeal primary, even in the absence of visible mucosal lesions on endoscopic examination [49][50][51]. This approach is particularly useful when small or anatomically concealed tumors evade detection. The evaluation process concludes within an interprofessional context. The standard of care for nasopharyngeal carcinoma involves a multidisciplinary team—typically convening within a tumor board setting—consisting of specialists in medical oncology, radiation oncology, surgical oncology, radiology, and pathology. This collaborative model ensures that diagnostic interpretation, staging, and treatment planning occur with the combined expertise necessary for managing such a complex and anatomically challenging malignancy [50][51].

**Treatment / Management**

Nonsurgical strategies constitute the cornerstone of therapy for nasopharyngeal carcinoma, largely because of the anatomical and biological characteristics of the disease. The nasopharynx is a deep, anatomically complex space surrounded by critical neurovascular and bony structures, making surgical exposure technically demanding and often morbid. In addition, most patients present with advanced-stage tumors that involve the skull base or adjacent osseous structures, rendering complete surgical resection infeasible or unsafe in the majority of cases. Consequently, surgery rarely serves as the primary treatment modality. Only in highly selected and exceptionally rare situations—typically small, early-stage primary tumors—has definitive surgical management been attempted, usually via minimally invasive endoscopic or transpalatal approaches. These experiences are primarily documented in small case series and remain the exception rather than standard practice [52]. Surgical intervention has a more clearly defined, albeit still limited, role in the salvage setting. In patients who experience persistent or recurrent disease within the nasopharynx following definitive chemoradiation, nasopharyngectomy—performed either through open approaches or, increasingly, via endoscopic methods—may be considered. In the largest reported series, salvage nasopharyngectomy achieved local control rates exceeding 80% at two years postoperatively, demonstrating that surgery can be effective in selected cases of localized failure [53]. Nonetheless, this approach is highly specialized and available only in experienced centers. As such, surgical management of nasopharyngeal carcinoma remains an infrequently used adjunct, reserved primarily for salvage rather than frontline treatment.

Given these constraints, nonsurgical management with radiation therapy, chemotherapy, or combined modality treatment is the primary therapeutic pathway for nearly all patients. The choice of regimen is determined by tumor stage, nodal status, overall disease burden, and patient comorbidities. Whenever feasible, patients should be encouraged to participate in clinical trials to access novel approaches and to contribute to ongoing efforts to optimize outcomes and reduce long-term toxicity [9]. Radiation therapy is the foundational treatment modality for nasopharyngeal carcinoma. The advent of intensity-modulated radiation therapy (IMRT) in the 1990s fundamentally transformed the therapeutic landscape by allowing precise conformal dose delivery to complex target volumes while sparing adjacent critical structures. IMRT has since become the standard of care. Consensus guidelines for target delineation in nasopharyngeal carcinoma have been developed to harmonize treatment planning, enhance tumor control, and minimize radiation-related injury to nearby organs at risk, including the eyes, brain, middle ears, salivary glands, and temporomandibular joints [54]. In stage I disease, radiation therapy alone is generally sufficient as a single-modality treatment, with chemotherapy introduced as a complement only in more advanced stages. Historically, radiation fields for nasopharyngeal carcinoma encompassed the entire bilateral nasopharynx and the regional nodal basins deemed at risk, including the retropharyngeal nodes and levels II through V of the neck. This strategy reflected the high propensity of nasopharyngeal carcinoma to spread

submucosally and metastasize to cervical lymph nodes. The fossa of Rosenmuller is the most common site of tumor origin in the nasopharynx, accounting for more than 80% of cases, and in up to 90% of patients the primary lesion remains unilateral even as it enlarges [55][56]. Recognition of this predominately unilateral pattern, together with advances in imaging and radiation planning, has supported a shift toward more selective target coverage. The NRG HN001 trial evaluated intentional sparing of the contralateral nasopharynx and adjacent normal structures in appropriate patients. This approach yielded a reduction of up to 62% in the volume of the lower-dose clinical target volume (CTV2) and decreased radiation dose to multiple critical organs by up to 33%, without compromising local control [57]. Such data have encouraged more individualized field design aimed at reducing late toxicity.

**Fig. 4: Treatment and management of nasopharyngeal cancer.**




The risk of nodal metastasis in nasopharyngeal carcinoma is high, and in many patients cervical lymphadenopathy is the first manifestation of disease. Except in stage I tumors, regional nodal basins must be routinely treated with radiation. While level II (jugulodigastric) lymph nodes were historically considered the most common metastatic site, modern imaging has clarified that retropharyngeal nodes are, in fact, the most frequently involved [58]. Nodal spread characteristically follows a stepwise pattern: involvement typically begins in the retropharyngeal nodes, followed by contiguous caudal extension along the deep cervical lymphatic chain to levels III, IV, and V. By contrast, level I nodes, intraparotid nodes, supraclavicular nodes, and level VI nodes appear to carry very low metastatic risk in nasopharyngeal carcinoma, as demonstrated in a meta-analysis encompassing more than 10,000 lymph nodes [59]. These findings support selective nodal irradiation strategies that target high-risk regions while sparing low-risk basins when appropriate. A particular consideration in treatment planning concerns level Ib and the submandibular glands. Whenever oncologically permissible, sparing the submandibular glands is desirable to mitigate xerostomia and improve long-term quality of life. In patients whose nodal involvement is limited and in whom level II lymph nodes are small and without extracapsular extension, level Ib may be omitted safely from the high-dose field. However, if level II nodes exceed 2 cm or display extracapsular spread, the risk of harboring occult disease in level Ib increases, and this region should be included in the target volume [60]. Current international guidelines recommend delivering approximately 70 Gy to the high-risk clinical

target volume and 50 to 60 Gy to low- and intermediate-risk regions, typically in conventional fractionation schedules [51].

Patterns-of-failure analyses have shown that most local recurrences arise within the high-dose region rather than at the periphery of the field, suggesting that marginal misses are uncommon and that failures are more likely due to intrinsic radioresistance or biological aggressiveness [61]. This has prompted increasing interest in dose de-escalation strategies aimed at reducing late radiation toxicity without compromising disease control. Emerging trials have explored gradient dose prescriptions, in which dose distributions are modulated more continuously rather than via traditional two-tiered schemes. Early results have been encouraging, showing favorable short-term control with potentially reduced toxicity [62]. Induction chemotherapy has also been investigated as a tool for risk stratification and de-escalation, particularly in children and adolescents, for whom the long-term consequences of facial and skull base irradiation can be especially severe. In this context, an initial course of systemic therapy can identify tumors that are highly chemosensitive, allowing for lower radiation doses in responders. Trials such as NPC-2003-GPOH/DCOG have reported promising outcomes using various induction chemotherapy protocols followed by reduced-dose radiation, with five-year event-free survival rates ranging from 77% to 91% using de-escalated doses between 45 and 68 Gy [63]. These findings support the feasibility of tailoring radiation intensity based on treatment response, particularly in younger patients.

Chemotherapy is an integral component of management for patients with locoregionally advanced nasopharyngeal carcinoma. A pivotal phase III intergroup study demonstrated that the addition of systemic chemotherapy to radiation therapy significantly improved both progression-free survival and overall survival in patients with stage III and locally advanced stage IV disease [64][65][66]. These results established concurrent chemoradiation as the standard of care for advanced stages and formed the basis of current international guidelines. The most recent joint recommendations from the American Society of Clinical Oncology and the Chinese Society of Clinical Oncology specify stage- and nodal status–dependent strategies [67]. In stage II disease, the decision to add chemotherapy hinges on lymph node involvement. Patients with T2N0 disease generally receive radiation alone, as chemotherapy has not been shown to provide clear benefit in this group. By contrast, patients with T1–2N1 disease are advised to undergo concurrent chemoradiation. For those with T3N0 tumors, concurrent chemoradiation is recommended, and induction or adjuvant chemotherapy may be considered as an additional measure. For all other stage III to IVA disease, concurrent chemoradiation is standard, supplemented by either induction or adjuvant chemotherapy, reflecting the higher risk of both locoregional and distant failure in this cohort [67].

Cisplatin remains the backbone of concurrent chemotherapeutic regimens in nasopharyngeal carcinoma and is the preferred agent where not contraindicated. It can be administered in one of two common schedules during radiation therapy: weekly dosing at 40 mg/m² for seven cycles, or a tri-weekly schedule of 100 mg/m² for three cycles [68][69][70][71][72]. Both approaches have demonstrated efficacy, and the choice between them is often influenced by institutional practice patterns, patient tolerance, and logistical considerations. For patients who cannot safely receive cisplatin due to renal impairment, ototoxicity, or other significant comorbidities, alternative platinum agents can be substituted. Options include carboplatin at an area-under-the-curve (AUC) of 5–6 administered every three weeks, nedaplatin at 100 mg/m² tri-weekly, or oxaliplatin at 70 mg/m² [67]. If any form of platinum-based therapy is contraindicated or poorly tolerated despite adjustment, concurrent use of nonplatinum agents such as capecitabine, tegafur, or 5-fluorouracil (5-FU) administered together with radiation offers an additional, though less well-validated, option [73]. Induction chemotherapy, given before concurrent chemoradiation, has gained increasing acceptance as a means to debulk large tumors, treat micrometastatic disease early, and improve distant control. Platinum-based combinations are recommended for all patients considered suitable candidates, as their use has been associated with clear survival advantages. A landmark phase II study published in 2009 reported improvement in overall survival from 68% to 94% when two cycles of docetaxel were added to a platinum-containing regimen, underscoring the value of taxane-platinum combinations [74]. Current induction regimens commonly include triplet or doublet combinations incorporating cisplatin and 5-FU

with or without docetaxel, or cisplatin with gemcitabine or capecitabine [75][76][77][78]. Examples include docetaxel at 60–75 mg/m² on day 1, cisplatin at 60–75 mg/m² on day 1, and 5-FU at 600–750 mg/m² per day as a continuous infusion over days 1 to 5; gemcitabine at 1000 mg/m² on days 1 and 8 combined with cisplatin 80 mg/m² on day 1; cisplatin at 80–100 mg/m² on day 1 with 5-FU at 800–1000 mg/m² per day as a continuous infusion over days 1 to 5; cisplatin 100 mg/m² on day 1 with capecitabine 2000 mg/m² per day on days 1 to 14; or a doublet of docetaxel 75 mg/m² and cisplatin 75 mg/m², both given on day 1. These regimens are typically delivered in two or three cycles prior to the start of concurrent chemoradiation.

Adjuvant chemotherapy, administered after completion of concurrent chemoradiation, is another strategy aimed at eradicating residual microscopic disease and reducing the risk of distant relapse. As with induction regimens, platinum-based agents are central to adjuvant therapy and should be used whenever possible [68]. A widely utilized regimen includes cisplatin at 80 mg/m² on day 1 or 20 mg/m² on days 1 through 5, combined with 5-FU at 1000 mg/m² per day as a continuous infusion on days 1 through 4 or 800 mg/m² per day as a continuous infusion on days 1 through 5. This combination is typically given every four weeks for three cycles [79][71] (A1). For patients unable to tolerate cisplatin, carboplatin can be substituted and combined with 5-FU, offering a less nephrotoxic and neurotoxic alternative while retaining antitumor activity [80]. In cases where significant contraindications preclude any platinum-based therapy, enrolling patients in clinical trials is strongly advised, as nonplatinum-based regimens remain investigational and should not be routinely employed outside of a research setting [67]. As the field evolves, ongoing studies are exploring novel systemic agents, including targeted therapies and immunotherapies, in combination with radiation and chemotherapy to further improve outcomes. Overall, the contemporary management of nasopharyngeal carcinoma is highly protocol-driven, multidisciplinary, and increasingly personalized. Radiation therapy—most often delivered via IMRT—forms the backbone of treatment, while chemotherapy, particularly cisplatin-based, is crucial in locoregionally advanced disease. Surgical intervention is reserved for highly selected primary tumors and, more commonly, for salvage of localized recurrences. The integration of imaging advances, refined radiation techniques, and sophisticated systemic regimens, together with participation in clinical trials, continues to improve survival and functional outcomes for patients with this challenging malignancy.

**Differential Diagnosis**

The differential diagnosis of nasopharyngeal carcinoma is broad because numerous benign, inflammatory, infectious, and malignant conditions can produce similar clinical manifestations. Careful evaluation is essential to distinguish nasopharyngeal carcinoma from other diseases that may present nasal obstruction, epistaxis, otitis media with effusion, cervical lymphadenopathy, or nonspecific head and neck symptoms. One of the most common benign mimickers is enlarged adenoids, which may occur in both children and adults. In the setting of HIV infection, lymphoid hyperplasia may be particularly pronounced, creating substantial nasopharyngeal obstruction that can resemble a neoplastic mass on physical examination or imaging. Antrochoanal polyps may also simulate nasopharyngeal carcinoma, as they extend posteriorly from the maxillary sinus through the choana into the nasopharynx, causing unilateral obstruction and possibly recurrent infections. Another locally aggressive but benign lesion, the inverting papilloma, can arise in the nasal cavity and paranasal sinuses, extending toward the nasopharynx and producing symptoms similar to a neoplastic process. Vascular malformations of the nasopharynx, although uncommon, may mimic malignancy because of their mass effect and tendency to cause epistaxis. These lesions, however, require careful diagnosis due to the risk of severe hemorrhage with biopsy. Nasal polyposis, particularly when unilateral, can raise suspicion for malignancy and must be differentiated from neoplastic lesions through endoscopic examination and imaging. Infectious mononucleosis caused by Epstein-Barr virus may produce cervical lymphadenopathy, fever, pharyngitis, and fatigue, occasionally accompanied by nasopharyngeal lymphoid hypertrophy, making it an important consideration in the diagnostic workup. Several malignancies can overlap clinically with nasopharyngeal carcinoma. Non-Hodgkin lymphoma—especially extranodal NK/T-cell lymphoma—commonly involves the sinonasal tract and nasopharynx and may present with ulceration, necrosis, mass formation, and cervical lymphadenopathy. Sarcomas of the

head and neck region, including rhabdomyosarcoma in children, may produce rapidly enlarging masses that involve the nasopharynx. Adenocarcinomas of the nasopharynx, although rare, can present similarly with local invasion and obstructive symptoms. Granulomatous diseases, such as Wegener granulomatosis (granulomatosis with polyangiitis), can mimic nasopharyngeal carcinoma through destructive sinonasal lesions and systemic symptoms. Rhinosporidiosis, a chronic granulomatous infection caused by Rhinosporidium seeberi, may form friable, polypoid masses in the nasopharynx that resemble neoplastic lesions on examination. Because these conditions span inflammatory, infectious, vascular, and malignant categories, a structured approach that integrates clinical assessment, imaging, endoscopy, and histopathologic confirmation is essential to accurately differentiate nasopharyngeal carcinoma from its many potential mimics [71][72][75].

**Prognosis**

The prognosis of nasopharyngeal carcinoma depends heavily on the stage at diagnosis, the biological characteristics of the tumor, and the patient's overall response to treatment. Early-stage disease, particularly stage I, is associated with a significantly more favorable outlook compared with more advanced presentations. According to available epidemiological survival data, the 5-year relative survival rate for stage I nasopharyngeal carcinoma is approximately 82%, highlighting the potential for long-term disease control when the cancer is confined to the nasopharynx and has not yet metastasized [81][82]. As the disease progresses to stage II, the survival rate decreases to around 72%, reflecting greater tumor bulk and higher likelihood of early regional spread. Stage IV disease, which represents locally advanced or metastatic cancer, carries the poorest outcomes, with a 5-year relative survival rate of approximately 49% [81][82]. These statistics underscore the importance of early detection and rapid intervention to improve long-term survival and quality of life. Following completion of initial treatment—which typically involves radiation therapy, chemotherapy, or a combination of both—ongoing surveillance is critical. Recurrences may occur locally, regionally, or at distant sites, particularly within the first several years after therapy. Therefore, regular follow-up with an oncologist is essential. Standard surveillance includes comprehensive head and neck examinations, nasal endoscopy to visualize the nasopharynx directly, and laboratory evaluation as indicated. Particular attention is paid to thyroid function testing, given the well-documented risk of radiation-induced hypothyroidism following treatment for head and neck cancers.

Circulating Epstein-Barr virus (EBV) DNA has emerged as a promising biomarker in both prognosis and posttreatment monitoring. Detectable EBV DNA following chemoradiotherapy is associated with an increased risk of disease persistence, recurrence, and poorer overall survival, making it a clinically important negative prognostic indicator [83]. Although EBV DNA testing has become established as a prognostic marker, its optimal role in routine posttreatment surveillance remains an area of active research and debate. Current evidence suggests potential utility in predicting early recurrence, but consensus guidelines regarding the timing, frequency, and interpretation of these tests have not yet been fully standardized [84]. The standard of care for posttreatment surveillance primarily relies on regular physical evaluations and nasal endoscopy. The timing and frequency of follow-up visits vary across institutions, but many experts advocate for intensive monitoring during the first two years after treatment—the period of highest recurrence risk. A commonly recommended schedule includes examinations every three months during the first 12 to 24 months. After this initial high-risk interval, follow-up may be extended to every 4 to 6 months during years three through five, and then annually in long-term survivors [85]. This staged approach ensures vigilant monitoring while balancing patient convenience and healthcare resource utilization. Imaging also plays a role in surveillance, particularly in the early posttreatment period. Many centers perform an initial PET-CT scan approximately three months after completion of radiotherapy to evaluate treatment response and detect residual or recurrent disease. If this scan is normal, a second PET-CT around one year posttreatment is often recommended to confirm ongoing remission [86]. In patients whose first two posttreatment PET-CT scans are negative, routine surveillance imaging may no longer be necessary in nonendemic regions, as the likelihood of recurrence becomes relatively low [87][88]. However, clinical judgment is essential, as surveillance protocols may need to be tailored to individual

patient risk factors, clinical symptoms, and emerging evidence. Overall, the prognosis for nasopharyngeal carcinoma has improved significantly over recent decades due to advances in imaging, radiation therapy techniques, and combined-modality treatment strategies. Despite this progress, the disease remains challenging because of its deep anatomic location, propensity for early lymphatic spread, and potential for late recurrences. Continuous follow-up, careful monitoring for treatment-related side effects, and adherence to evolving surveillance guidelines remain essential components of comprehensive survivorship care [86][87].

**Complications**

Nasopharyngeal carcinoma and its treatment are associated with a wide spectrum of potential complications that may arise during therapy or long after completion of treatment. These complications reflect both the biological behavior of the tumor and the intensity of multimodality therapy required to achieve disease control. Treatment-related toxicities are particularly prominent because radiation therapy and chemotherapy remain the mainstays of management. During radiation therapy, patients frequently develop acute mucositis involving the nasopharynx, oropharynx, and oral cavity. This manifests as painful inflammation, ulceration, and difficulty swallowing, which can impair oral intake and lead to weight loss, dehydration, and the need for nutritional support. Concomitantly, radiation-induced xerostomia often emerges as salivary gland function declines, resulting in thick, tenacious secretions, impaired taste, difficulty speaking and eating, and a markedly increased risk of dental caries and oral infections. Radiation dermatitis over the irradiated skin surfaces, particularly in the neck region, may cause erythema, desquamation, and discomfort. Fatigue is also common, reflecting systemic effects of treatment and the overall physiological burden of malignancy. Chemotherapy introduces an additional layer of toxicity. Systemic agents such as cisplatin and other cytotoxic drugs can induce nausea, vomiting, anorexia, alopecia, and myelosuppression. Myelosuppression leads to neutropenia, anemia, and thrombocytopenia, which in turn increase susceptibility to infections, reduce exercise tolerance, and heighten the risk of bleeding. Because both cancer and its treatments compromise the immune system, patients may be vulnerable to opportunistic infections and require careful monitoring and prophylactic strategies. Over time, cumulative nephrotoxicity, ototoxicity, and neurotoxicity from certain chemotherapeutic agents can further compromise quality of life [87].

Long-term and late complications are particularly salient in nasopharyngeal carcinoma survivors because many structures within or near the radiation field are highly sensitive. Persistent xerostomia is one of the most frequent and debilitating late effects, resulting from irreversible damage to the salivary glands. Chronic dry mouth may cause ongoing difficulty with mastication, swallowing, and speech and necessitates rigorous dental care to prevent rampant caries and osteoradionecrosis of the jaw. Hearing loss is another important complication and may be conductive, sensorineural, or mixed in nature. Conductive hearing loss can arise from chronic eustachian tube dysfunction and middle ear effusion, whereas sensorineural hearing loss may be related to cochlear damage from radiation or the ototoxicity of platinum-based chemotherapy. Tinnitus and balance disturbances can further affect daily functioning. Radiation to the skull base and brain structures may also contribute to neurocognitive sequelae. Some patients report deficits in memory, attention, or processing speed, which may impact occupational performance and psychosocial well-being. Endocrine dysfunction, including hypothyroidism secondary to radiation exposure of the thyroid gland, is another frequent late complication, necessitating long-term hormonal monitoring and replacement therapy. Cranial neuropathies may occur due to tumor invasion or radiation-induced fibrosis, resulting in facial numbness, diplopia, dysphagia, or vocal cord dysfunction. Despite aggressive treatment, nasopharyngeal carcinoma retains a risk of local recurrence and distant metastasis. Metastatic spread commonly involves the bone, lung, and liver, leading to pain, pathological fractures, respiratory compromise, or hepatic dysfunction. Local recurrence within the nasopharynx or neck may necessitate reirradiation, salvage surgery, or systemic therapy, each associated with additional morbidity. Finally, long-term survivors are at increased risk of developing second primary malignancies, which may be related to prior radiation, chemotherapy, persistent viral infection, or shared environmental and genetic risk factors. These secondary cancers may occur within the head and neck region, lungs, or other organs, reinforcing the need for ongoing

surveillance and preventive strategies. Collectively, these complications highlight the importance of multidisciplinary care, survivorship planning, and proactive symptom management throughout the disease trajectory [86][87].

**Patient Education**

Deterrence and patient education in the context of nasopharyngeal carcinoma aim to reduce the risk of disease development, promote early detection, and empower patients and communities with knowledge about risk factors, symptoms, and available treatments. Because nasopharyngeal carcinoma demonstrates a strong geographic and ethnic predilection, particularly in populations from Southern China and parts of Southeast Asia, public health and educational initiatives must be tailored to high-risk groups. Education begins with emphasizing modifiable risk factors. Individuals should be informed about the role of tobacco use and excessive alcohol consumption as potential contributors to head and neck malignancies, especially in nonendemic regions. Counseling to avoid smoking and limit alcohol intake, supported by smoking cessation programs and behavioral interventions, can play a crucial role in reducing overall cancer risk. Dietary counseling is another important component of deterrence. In endemic areas, high consumption of salted and preserved foods containing nitrosamines, such as salted fish, has been associated with increased nasopharyngeal carcinoma risk. Educational campaigns can promote diets rich in fresh fruits, vegetables, and minimally processed foods while discouraging heavy reliance on preserved or salted products. Coupled with general lifestyle recommendations—including regular physical activity and maintenance of a healthy body weight—these measures support overall health and may help mitigate cancer risk. Because Epstein-Barr virus infection is strongly linked to nasopharyngeal carcinoma, particularly in nonkeratinizing subtypes, educational efforts should also address basic information about EBV. While EBV is ubiquitous and not entirely preventable, awareness of its association with certain cancers can prompt individuals, especially those with a family history of nasopharyngeal carcinoma or residing in high-incidence regions, to remain vigilant about persistent or unusual symptoms. In some settings, information about hygiene, reducing saliva-sharing practices, and general infection control may be highlighted, although these measures cannot fully eliminate EBV exposure. Early detection is a central theme in patient education. Individuals should be encouraged to seek medical evaluation for symptoms such as persistent unilateral nasal obstruction, recurrent epistaxis, unexplained hearing loss or middle ear effusion, chronic headaches, facial pain, or a painless neck mass. In high-risk populations, primary care providers and community health workers play a pivotal role in recognizing these warning signs and expediting referral to otolaryngology or oncology specialists. Education campaigns may use community lectures, print materials, digital media, and culturally appropriate outreach to communicate these messages [86].

For those with a strong family history of nasopharyngeal carcinoma or other relevant cancers, genetic counseling and risk assessment services may be appropriate. Although specific susceptibility genes are still being elucidated, counseling can help individuals understand their relative risk and consider enhanced surveillance strategies. In some endemic regions, screening programs using EBV DNA testing or serological markers have been explored. Patients and at-risk individuals should be informed about the potential benefits and limitations of such tests, where available, and the importance of follow-up if abnormal results are detected. Patient education does not end at diagnosis. Individuals diagnosed with nasopharyngeal carcinoma should receive clear, comprehensible information about their disease, treatment options, potential side effects, and expected outcomes. Understanding the rationale for combined-modality therapy, the importance of completing treatment, and the need for long-term follow-up fosters adherence and shared decision-making. Education on managing treatment-related complications—such as maintaining oral hygiene to prevent dental complications, recognizing signs of infection, and addressing nutritional challenges—helps patients maintain function and quality of life during and after therapy. Ultimately, deterrence and education function synergistically: by improving awareness of risk factors and symptoms, they enhance opportunities for prevention and earlier diagnosis, while ongoing patient-centered education supports better treatment experiences and survivorship [87].

## Other Issues

Several key concepts, or "pearls," are essential for clinicians and healthcare teams involved in the diagnosis and management of nasopharyngeal carcinoma. First, nasopharyngeal carcinoma exhibits a highly distinctive geographic and ethnic distribution, with a strikingly higher incidence in Southeast Asia, particularly in Southern China and neighboring regions. Recognizing this epidemiologic pattern is critical when evaluating symptoms in patients of Asian ancestry or from endemic areas, even if they now reside in low-incidence countries. In such individuals, symptoms like a unilateral middle ear effusion, persistent nasal obstruction, or a painless cervical lymph node should raise suspicion for nasopharyngeal carcinoma. Epstein-Barr virus plays a central etiologic role in most nonkeratinizing nasopharyngeal carcinomas, particularly in endemic regions. The strong association between EBV infection and tumor development underscores the importance of considering viral oncogenesis in both diagnosis and prognosis. Genetic factors, including family history and specific HLA or MHC class I variants, appear to modulate susceptibility, while environmental factors such as consumption of preserved foods rich in nitrosamines further contribute to risk. In nonendemic regions, traditional carcinogens such as tobacco and alcohol may play more prominent roles, especially in keratinizing type 1 tumors, which resemble conventional head and neck squamous cell carcinomas. From a pathologic standpoint, the World Health Organization classification divides nasopharyngeal carcinoma into three main histologic subtypes: keratinizing squamous cell carcinoma (type 1), differentiated nonkeratinizing carcinoma (type 2), and undifferentiated carcinoma (type 3). Types 2 and 3 are typically EBV-related, more responsive to radiation and chemotherapy, and predominate in high-incidence populations. Clinical presentation often includes a painless neck mass, otitis media with effusion due to eustachian tube obstruction, nasal obstruction, epistaxis, and other head and neck symptoms that may be subtle initially. Because the nasopharynx is anatomically concealed, tumors frequently go unnoticed until they reach advanced stages, making high clinical suspicion essential [86][87].

Diagnosis is confirmed through histologic examination, usually obtained via endoscopic biopsy of a nasopharyngeal mass. Imaging with CT and MRI is indispensable for staging, providing detailed assessment of local invasion, nodal involvement, and skull base extension. PET-CT contributes to the evaluation of distant metastasis and helps in comprehensive staging and treatment planning. Ancillary tests, such as EBV DNA quantification, may be used for screening in high-risk regions and for monitoring disease response or recurrence, although their roles continue to be refined. Therapeutically, chemotherapy is frequently used alongside radiation, particularly in stages II to IV, where concurrent chemoradiation with cisplatin-based regimens has become standard. Surgery, in contrast, is rarely employed as primary treatment due to the challenging anatomy of the nasopharynx and the high efficacy of radiation-based strategies. Instead, surgical intervention is generally reserved for salvage situations after treatment failure or for managing complications. Prognosis is strongly stage-dependent, with early-stage disease associated with significantly better outcomes compared to advanced-stage or metastatic disease. Other important considerations include long-term survivorship issues, such as management of xerostomia, hearing loss, hypothyroidism, and neurocognitive changes, which may arise as sequelae of treatment. Awareness of the potential for second primary malignancies and psychosocial impact further emphasizes the need for comprehensive, long-term follow-up care. Together, these pearls and related issues provide a concise yet nuanced framework for understanding the complexities of nasopharyngeal carcinoma in clinical practice [87].

## Enhancing Healthcare Team Outcomes

Optimal care for patients with nasopharyngeal carcinoma relies on a highly coordinated, interprofessional approach that integrates the expertise of multiple healthcare disciplines. Because this malignancy requires complex diagnostic workups, advanced radiation planning, systemic therapy, and prolonged follow-up, no single provider can address all aspects of care effectively. Physicians and advanced practice providers in otolaryngology, medical oncology, and radiation oncology must be proficient in recognizing early clinical manifestations, performing diagnostic procedures, staging the disease accurately, and formulating evidence-

based treatment plans. Their collaboration is especially critical during tumor board meetings, where imaging, pathology, and clinical status are reviewed collectively to reach consensus on management strategies tailored to each patient. Radiologists and pathologists play fundamental roles in this process. Head and neck radiologists interpret CT, MRI, and PET-CT scans, delineating the extent of primary tumor invasion, nodal involvement, and possible distant metastases. Accurate imaging interpretation is vital for staging, target volume delineation in radiation planning, and assessment of treatment response. Pathologists confirm the diagnosis, determine histologic subtype, and perform ancillary tests such as immunohistochemistry for epithelial markers and EBV-related proteins, as well as molecular testing when necessary. Clear, timely communication between radiologists, pathologists, and treating clinicians ensures that diagnostic information is accurately translated into clinical decisions [87].

Nurses are indispensable in the day-to-day management of nasopharyngeal carcinoma patients. They provide education about treatment regimens, anticipated side effects, and self-care strategies, such as maintaining oral hygiene, managing mucositis, and recognizing early signs of infection or dehydration. During therapy, nurses monitor patients for acute toxicities, coordinate supportive interventions, and reinforce adherence to radiation and chemotherapy schedules. In survivorship, they continue to support patients in managing chronic complications, facilitating referrals to dental care, speech and swallowing therapy, audiology, endocrinology, and psychosocial services as needed. Pharmacists contribute specialized knowledge regarding chemotherapy agents, antiemetics, analgesics, and supportive medications. They help design safe and effective dosing regimens, review potential drug interactions, and counsel patients on medication adherence and side effect management. Their involvement is especially valuable when adjusting treatment for comorbidities, renal or hepatic impairment, or when transitioning between inpatient and outpatient care. Allied health professionals further enhance outcomes through targeted interventions. Dietitians assist in managing nutritional challenges arising from dysphagia, mucositis, and altered taste, working to prevent malnutrition and maintain strength during treatment. Speech and language therapists and swallowing specialists help patients adapt to changes in speech or swallowing function, particularly after high-dose radiation or salvage surgery. Social workers and psychologists address emotional, social, and financial concerns, which can significantly influence treatment adherence and quality of life [88].

Effective interprofessional communication is the foundation of this collaborative model. Regular multidisciplinary meetings, clearly documented care plans, and structured handovers ensure continuity and coherence in patient management. Patient navigation services can help coordinate appointments, facilitate access to rehabilitation and supportive care, and assist patients in understanding complex treatment pathways. An ethical and culturally sensitive approach is also central, particularly when caring for patients from diverse ethnic backgrounds or endemic regions, where beliefs and expectations about illness and treatment may differ. By fostering mutual respect, shared decision-making, and clear communication among team members, healthcare systems can improve clinical outcomes, reduce treatment-related complications, and enhance patient satisfaction. In nasopharyngeal carcinoma, where treatment is intensive and long-term follow-up is essential, such an integrated interprofessional approach is not merely beneficial but indispensable for delivering high-quality, patient-centered care [88].

**Conclusion:**

In conclusion, nasopharyngeal carcinoma represents a unique oncologic challenge due to its strong viral association, anatomic complexity, and the intensity of required treatment. The cornerstone of management for non-metastatic disease is definitive chemoradiotherapy, with cisplatin-based concurrent regimens and IMRT forming the modern standard of care. This approach has significantly improved locoregional control and survival, particularly for the more common nonkeratinizing subtypes. However, the aggressive treatment paradigm leads to a substantial burden of acute and chronic toxicities, such as xerostomia, dysphagia, ototoxicity, and endocrine dysfunction, which profoundly impact quality of life and necessitate dedicated survivorship care. Achieving the best possible outcomes extends beyond technical treatment delivery. It fundamentally depends on a highly integrated, interprofessional healthcare model. From initial

diagnosis through long-term follow-up, effective collaboration between otolaryngologists, medical and radiation oncologists, radiologists, pathologists, nurses, pharmacists, dietitians, and rehabilitation specialists is indispensable. This team-based approach ensures accurate staging, personalized treatment planning, meticulous supportive care during therapy, and proactive management of late effects. Therefore, the successful management of NPC patients undergoing chemo-radiotherapy is a testament to the synergy of advanced medical technology and coordinated, patient-centered teamwork.

**References:**

1. Wu Z, Qi B, Lin FF, Zhang L, He Q, Li FP, Wang H, Han YQ, Yin WJ. Characteristics of local extension based on tumor distribution in nasopharyngeal carcinoma and proposed clinical target volume delineation. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2023 Jun:183():109595. doi: 10.1016/j.radonc.2023.109595.
2. Bei JX, Su WH, Ng CC, Yu K, Chin YM, Lou PJ, Hsu WL, McKay JD, Chen CJ, Chang YS, Chen LZ, Chen MY, Cui Q, Feng FT, Feng QS, Guo YM, Jia WH, Khoo AS, Liu WS, Mo HY, Pua KC, Teo SH, Tse KP, Xia YF, Zhang H, Zhou GQ, Liu JJ, Zeng YX, Hildesheim A, International Nasopharyngeal Carcinoma (NPC) Genetics Working Group. A GWAS Meta-analysis and Replication Study Identifies a Novel Locus within CLPTM1L/TERT Associated with Nasopharyngeal Carcinoma in Individuals of Chinese Ancestry. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2016 Jan:25(1):188-192. doi: 10.1158/1055-9965.EPI-15-0144.
3. Challapalli SD, Simpson MC, Adjei Boakye E, Walker RJ, Antisdel JL, Ward GM, Osazuwa-Peters N. Survival differences in nasopharyngeal carcinoma among racial and ethnic minority groups in the United States: A retrospective cohort study. Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery. 2019 Jan:44(1):14-20. doi: 10.1111/coa.13225.
4. Liao LJ, Hsu WL, Chen CJ, Chiu YL. Feature Reviews of the Molecular Mechanisms of Nasopharyngeal Carcinoma. Biomedicines. 2023 May 25:11(6):. doi: 10.3390/biomedicines11061528.
5. Kamara S, Guo Y, Wen H, Liu Y, Liu L, Zheng M, Zhang J, Zhou L, Chen J, Zhu S, Zhang L. Novel Bifunctional Affibody Molecules with Specific Binding to Both EBV LMP1 and LMP2 for Targeted Therapy of Nasopharyngeal Carcinoma. International journal of molecular sciences. 2023 Jun 14:24(12):. doi: 10.3390/ijms241210126.
6. Xiong Y, Yuan M, Liu Z, Huang J, Bi J, Pi G, Li Y, Li Y, He H, Verma V, Tian S, Han G. Long-Term Outcomes of Nasopharyngeal Carcinoma by Epstein-Barr Virus Status in the Chinese Population: A Multicenter Investigation. Journal of clinical medicine. 2023 Apr 20:12(8):. doi: 10.3390/jcm12083005.
7. Benesch MGK, O'Brien SBL. Epidemiology of Undifferentiated Carcinomas. Cancers. 2022 Nov 25:14(23):. doi: 10.3390/cancers14235819.
8. Geng X, Hao F, Han G, Zhang Y, Qin P. Dural and Multiple Brain Metastases From Basaloid Nasopharyngeal Carcinoma: Case Report and Literature Review. Frontiers in oncology. 2021:11():665652. doi: 10.3389/fonc.2021.665652.
9. Xu K, De Ravin E, Suresh N, Brody RM, Rajasekaran K. A comprehensive review and characterization of nasopharyngeal carcinoma clinical trials. World journal of otorhinolaryngology - head and neck surgery. 2023 Jun:9(2):174-182. doi: 10.1002/wjo2.80.
10. Fu ZT, Guo XL, Zhang SW, Zeng HM, Sun KX, Chen WQ, He J. [Incidence and mortality of nasopharyngeal carcinoma in China, 2014]. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2018 Aug 23:40(8):566-571. doi: 10.3760/cma.j.issn.0253-3766.2018.08.002.
11. Adoga AA, Kokong DD, Ma'an ND, Silas OA, Dauda AM, Yaro JP, Mugu JG, Mgbachi CJ, Yabak CJ. The epidemiology, treatment, and determinants of outcome of primary head and neck cancers at the Jos

University Teaching Hospital. South Asian journal of cancer. 2018 Jul-Sep:7(3):183-187. doi: 10.4103/sajc.sajc_15_18.
12. Blanchard P, Nguyen F, Moya-Plana A, Pignon JP, Even C, Bidault F, Temam S, Ruffier A, Tao Y. [New developments in the management of nasopharyngeal carcinoma]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. 2018 Oct:22(6-7):492-495. doi: 10.1016/j.canrad.2018.06.003.
13. Romdhoni AC, Rejeki PS, Guo HR, Milla C, Melbiarta RR, Visuddho V, Nugraha D. Risk Factors Associated with Nasopharyngeal Cancer Incidences in Indonesia: A Systematic Review and Meta-Analysis. Asian Pacific journal of cancer prevention : APJCP. 2023 Apr 1:24(4):1105-1111. doi: 10.31557/APJCP.2023.24.4.1105.
14. Kondo S, Okuno Y, Murata T, Dochi H, Wakisaka N, Mizokami H, Moriyama-Kita M, Kobayashi E, Kano M, Komori T, Hirai N, Ueno T, Nakanishi Y, Endo K, Sugimoto H, Kimura H, Yoshizaki T. EBV genome variations enhance clinicopathological features of nasopharyngeal carcinoma in a non-endemic region. Cancer science. 2022 Jul:113(7):2446-2456. doi: 10.1111/cas.15381.
15. Wee JT, Ha TC, Loong SL, Qian CN. Is nasopharyngeal cancer really a "Cantonese cancer"? Chinese journal of cancer. 2010 May:29(5):517-26
16. Li YC, Gao ZL, Liu KJ, Tian JY, Yang BY, Rahman ZU, Yang LQ, Zhang SH, Li CT, Achilli A, Semino O, Torroni A, Kong QP. Mitogenome evidence shows two radiation events and dispersals of matrilineal ancestry from northern coastal China to the Americas and Japan. Cell reports. 2023 May 30:42(5):112413. doi: 10.1016/j.celrep.2023.112413.
17. Lian M. Salted fish and processed foods intake and nasopharyngeal carcinoma risk: a dose-response meta-analysis of observational studies. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 2022 May:279(5):2501-2509. doi: 10.1007/s00405-021-07210-9.
18. Kara B, Ertan K, Düzova M, Çağlayan AO, Köksal Y. Familial clustering of nasopharyngeal carcinoma in the family of an adolescent with nasopharyngeal carcinoma. The Turkish journal of pediatrics. 2022:64(6):1130-1135. doi: 10.24953/turkjped.2022.62.
19. Zhang WL, Zhang JB, Wang TM, Wu YX, He YQ, Xue WQ, Liao Y, Deng CM, Li DH, Wu ZY, Yang DW, Zheng XH, Li XZ, Zhou T, Zhang PF, Zhang SD, Hu YZ, Jia WH. Genomic landscape of Epstein-Barr virus in familial nasopharyngeal carcinoma. The Journal of general virology. 2022 Mar:103(3):. doi: 10.1099/jgv.0.001728.
20. Wang L, Song YL, Huang SM, Tao HX, Zhao YQ, Yan N, Xu DY. [The clinical significance of EBV DNA analysis in nasopharyngeal carcinoma screening]. Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery. 2018 Feb:32(4):298-301. doi: 10.13201/j.issn.1001-1781.2018.04.014.
21. Kong FF, Pan GS, Du CR, Ni MS, Zhai RP, He XY, Shen CY, Lu XG, Hu CS, Ying HM. Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2023 Aug:185():109721. doi: 10.1016/j.radonc.2023.109721.
22. Gihbid A, Benzeid R, Faouzi A, El Alami I, Tawfiq N, Benchakroun N, Bendahhou K, Benider A, Guensi A, Khaali W, Chaoui I, El Mzibri M, Cadi R, Khyatti M. The Dynamic Change in Plasma Epstein-Barr Virus DNA Load over a Long-Term Follow-Up Period Predicts Prognosis in Nasopharyngeal Carcinoma. Viruses. 2022 Dec 25:15(1):. doi: 10.3390/v15010066.
23. Liu P, Xue XM, Zhang C, Zhou HW, Ding ZW, Jiang YK, Wang L, Shen WD, Yang SM, Wang FY. Prognostic factor analysis in patients with early-stage nasopharyngeal carcinoma in the USA. Future oncology (London, England). 2023 May:19(15):1063-1072. doi: 10.2217/fon-2022-0609.
24. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006 Oct:15(10):1765-77

25. Friborg J, Wohlfahrt J, Melbye M. Familial risk and clustering of nasopharyngeal carcinoma in Guangdong, China. Cancer. 2005 Jan 1:103(1):211; author reply 211-2
26. Liao HM, Liu H, Chin PJ, Li B, Hung GC, Tsai S, Otim I, Legason ID, Ogwang MD, Reynolds SJ, Kerchan P, Tenge CN, Were PA, Kuremu RT, Wekesa WN, Masalu N, Kawira E, Ayers LW, Pfeiffer RM, Bhatia K, Goedert JJ, Lo SC, Mbulaiteye SM. Epstein-Barr Virus in Burkitt Lymphoma in Africa Reveals a Limited Set of Whole Genome and LMP-1 Sequence Patterns: Analysis of Archival Datasets and Field Samples From Uganda, Tanzania, and Kenya. Frontiers in oncology. 2022:12():812224. doi: 10.3389/fonc.2022.812224. Epub 2022 Mar 7
27. Reffai A, Mesmoudi M, Derkaoui T, Ghailani Nourouti N, Barakat A, Sellal N, Mallick P, Bennani Mechita M. Epidemiological Profile and Clinicopathological, Therapeutic, and Prognostic Characteristics of Nasopharyngeal Carcinoma in Northern Morocco. Cancer control : journal of the Moffitt Cancer Center. 2021 Jan-Dec:28():10732748211050587. doi: 10.1177/10732748211050587.
28. Bray F, Haugen M, Moger TA, Tretli S, Aalen OO, Grotmol T. Age-incidence curves of nasopharyngeal carcinoma worldwide: bimodality in low-risk populations and aetiologic implications. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008 Sep:17(9):2356-65. doi: 10.1158/1055-9965.EPI-08-0461.
29. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018 Nov:68(6):394-424. doi: 10.3322/caac.21492.
30. Li WZ, Lv SH, Liu GY, Liang H, Xia WX, Xiang YQ. Age-dependent changes of gender disparities in nasopharyngeal carcinoma survival. Biology of sex differences. 2021 Jan 30:12(1):18. doi: 10.1186/s13293-021-00361-8.
31. Liu F, Xie WB, Zhou LY, Liu YH, Fang WY, Yao KT. [Effect of A20 gene induced silencing on the biological behaviors of human nasopharyngeal carcinoma cell]. Zhonghua yi xue za zhi. 2018 Jun 26:98(24):1956-1961. doi: 10.3760/cma.j.issn.0376-2491.2018.24.013.
32. Xu M, Yao Y, Chen H, Zhang S, Cao SM, Zhang Z, Luo B, Liu Z, Li Z, Xiang T, He G, Feng QS, Chen LZ, Guo X, Jia WH, Chen MY, Zhang X, Xie SH, Peng R, Chang ET, Pedergnana V, Feng L, Bei JX, Xu RH, Zeng MS, Ye W, Adami HO, Lin X, Zhai W, Zeng YX, Liu J. Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma. Nature genetics. 2019 Jul:51(7):1131-1136. doi: 10.1038/s41588-019-0436-5.
33. Su WH, Hildesheim A, Chang YS. Human leukocyte antigens and epstein-barr virus-associated nasopharyngeal carcinoma: old associations offer new clues into the role of immunity in infection-associated cancers. Frontiers in oncology. 2013 Dec 9:3():299. doi: 10.3389/fonc.2013.00299.
34. Hau PM, Lung HL, Wu M, Tsang CM, Wong KL, Mak NK, Lo KW. Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma. Frontiers in oncology. 2020:10():600. doi: 10.3389/fonc.2020.00600.
35. Tsao SW, Tsang CM, Lo KW. Epstein-Barr virus infection and nasopharyngeal carcinoma. Philosophical transactions of the Royal Society of London. Series B, Biological sciences. 2017 Oct 19:372(1732):. doi: 10.1098/rstb.2016.0270.
36. Tsao SW, Tsang CM, To KF, Lo KW. The role of Epstein-Barr virus in epithelial malignancies. The Journal of pathology. 2015 Jan:235(2):323-33. doi: 10.1002/path.4448.
37. Dawson CW, Port RJ, Young LS. The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Seminars in cancer biology. 2012 Apr:22(2):144-53. doi: 10.1016/j.semcancer.2012.01.004.
38. Raab-Traub N. Nasopharyngeal Carcinoma: An Evolving Role for the Epstein-Barr Virus. Current topics in microbiology and immunology. 2015:390(Pt 1):339-63. doi: 10.1007/978-3-319-22822-8_14.
39. Wang JH, Zhu H, Shang YF, Wang YJ, Li Y, Wang L, Huang SS, Lyu XQ. [Nasopharyngeal carcinoma with non-squamous immunophenotype: a clinicopathological analysis of 23 cases]. Zhonghua bing li xue za zhi = Chinese journal of pathology. 2022 Jun 8:51(6):500-505. doi: 10.3760/cma.j.cn112151-20211111-00816.

40. Kumari S, Pandey S, Verma M, Rana AK, Kumari S. Clinicopathological Challenges in Tumors of the Nasal Cavity and Paranasal Sinuses: Our Experience. Cureus. 2022 Sep:14(9):e29128. doi: 10.7759/cureus.29128.
41. Zhai C, Yuan C, Sun J, Song W, Wang S, Lin L. Clinical and Histopathologic Analyses of Nasopharyngeal Hyalinizing Clear Cell Carcinoma: A Series of 26 Cases With Molecular Confirmation. The American journal of surgical pathology. 2023 Oct 1:47(10):1168-1175. doi: 10.1097/PAS.0000000000002092.
42. Tay JK, Siow CH, Goh HL, Lim CM, Hsu PP, Chan SH, Loh KS. A comparison of EBV serology and serum cell-free DNA as screening tools for nasopharyngeal cancer: Results of the Singapore NPC screening cohort. International journal of cancer. 2020 May 15:146(10):2923-2931. doi: 10.1002/ijc.32774.
43. Ito T, Majima H, Ozawa T, Maeda M, Iwamoto S, Hirayama M, Azuma E. An Unusual Presentation of Nasopharyngeal Carcinoma as Lemierre Syndrome. The American journal of case reports. 2019 Feb 28:20():263-267. doi: 10.12659/AJCR.913755.
44. Weber AL, al-Arayedh S, Rashid A. Nasopharynx: clinical, pathologic, and radiologic assessment. Neuroimaging clinics of North America. 2003 Aug:13(3):465-83
45. Goh J, Lim K. Imaging of nasopharyngeal carcinoma. Annals of the Academy of Medicine, Singapore. 2009 Sep:38(9):809-16
46. King AD, Teo P, Lam WW, Leung SF, Metreweli C. Paranasopharyngeal space involvement in nasopharyngeal cancer: detection by CT and MRI. Clinical oncology (Royal College of Radiologists (Great Britain)). 2000:12(6):397-402
47. King AD, Vlantis AC, Bhatia KS, Zee BC, Woo JK, Tse GM, Chan AT, Ahuja AT. Primary nasopharyngeal carcinoma: diagnostic accuracy of MR imaging versus that of endoscopy and endoscopic biopsy. Radiology. 2011 Feb:258(2):531-7. doi: 10.1148/radiol.10101241.
48. Fong D, Bhatia KS, Yeung D, King AD. Diagnostic accuracy of diffusion-weighted MR imaging for nasopharyngeal carcinoma, head and neck lymphoma and squamous cell carcinoma at the primary site. Oral oncology. 2010 Aug:46(8):603-6. doi: 10.1016/j.oraloncology.2010.05.004.
49. Yang SP, Li JF, Zhou P, Lian CL, Chen DX, Li ZJ, Wu SG. Biopsy of cervical lymph node does not impact the survival of nasopharyngeal carcinoma. Cancer medicine. 2021 Oct:10(19):6687-6696. doi: 10.1002/cam4.4204.
50. Ye JX, Liang X, Wei J, Zhou J, Liao Y, Lu YL, Tang XQ, Wang AY, Tang Y. Compliance with National Guidelines on the Treatment of Stage II–IVB Nasopharyngeal Carcinoma in a Regional Cancer Center of Southern China. Asian Pacific journal of cancer prevention : APJCP. 2018 Jan 27:19(1):115-120
51. Lee AW, Ng WT, Pan JJ, Poh SS, Ahn YC, AlHussain H, Corry J, Grau C, Grégoire V, Harrington KJ, Hu CS, Kwong DL, Langendijk JA, Le QT, Lee NY, Lin JC, Lu TX, Mendenhall WM, O'Sullivan B, Ozyar E, Peters LJ, Rosenthal DI, Soong YL, Tao Y, Yom SS, Wee JT. International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2018 Jan:126(1):25-36. doi: 10.1016/j.radonc.2017.10.032.
52. Tsang RK, Wei WI. Salvage surgery for nasopharyngeal cancer. World journal of otorhinolaryngology - head and neck surgery. 2015 Sep:1(1):34-43. doi: 10.1016/j.wjorl.2015.09.006.
53. Tsang RK, Ng WT. Treatment of persistent/recurrent nodal disease in nasopharyngeal cancer. Current opinion in otolaryngology & head and neck surgery. 2021 Apr 1:29(2):86-92. doi: 10.1097/MOO.0000000000000687.
54. Lee AW, Ng WT, Pan JJ, Chiang CL, Poh SS, Choi HC, Ahn YC, AlHussain H, Corry J, Grau C, Grégoire V, Harrington KJ, Hu CS, Kwong DL, Langendijk JA, Le QT, Lee NY, Lin JC, Lu TX, Mendenhall WM, O'Sullivan B, Ozyar E, Peters LJ, Rosenthal DI, Sanguineti G, Soong YL, Tao Y, Yom SS, Wee JT. International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. International journal of radiation oncology, biology, physics. 2019 Nov 1:105(3):567-580. doi: 10.1016/j.ijrobp.2019.06.2540.

55. Li AC, Zhang YY, Zhang C, Wang DS, Xu BH. Pathologic study of tumour extension for clinically localized unilateral nasopharyngeal carcinoma: Should the contralateral side be included in the clinical target volume? Journal of medical imaging and radiation oncology. 2018 May 28:():. doi: 10.1111/1754-9485.12741.
56. Sun Y, Yu XL, Zhang GS, Liu YM, Tao CJ, Guo R, Tang LL, Zhang R, Guo Y, Ma J. Reduction of clinical target volume in patients with lateralized cancer of the nasopharynx and without contralateral lymph node metastasis receiving intensity-modulated radiotherapy. Head & neck. 2016 Apr:38 Suppl 1():E468-72. doi: 10.1002/hed.24020.
57. Sanford NN, Lau J, Lam MB, Juliano AF, Adams JA, Goldberg SI, Lu HM, Lu YC, Liebsch NJ, Curtin HD, Chan AW. Individualization of Clinical Target Volume Delineation Based on Stepwise Spread of Nasopharyngeal Carcinoma: Outcome of More Than a Decade of Clinical Experience. International journal of radiation oncology, biology, physics. 2019 Mar 1:103(3):654-668. doi: 10.1016/j.ijrobp.2018.10.006.
58. Ng WT, Chow JCH, Beitler JJ, Corry J, Mendenhall W, Lee AWM, Robbins KT, Nuyts S, Saba NF, Smee R, Stokes WA, Strojan P, Ferlito A. Current Radiotherapy Considerations for Nasopharyngeal Carcinoma. Cancers. 2022 Nov 24:14(23):. doi: 10.3390/cancers14235773.
59. Ho FC, Tham IW, Earnest A, Lee KM, Lu JJ. Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: a meta-analysis of clinical evidence. BMC cancer. 2012 Mar 21:12():98. doi: 10.1186/1471-2407-12-98.
60. Wang G, Huang C, Yang K, Guo R, Qiu Y, Li W, Mao Y, Tang L, Ma J. Neck level Ib-sparing versus level Ib-irradiation in intensity-modulated radiotherapy for the treatment of nasopharyngeal carcinoma with high-risk factors: A propensity score-matched cohort study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2022 Dec:177():205-213. doi: 10.1016/j.radonc.2022.11.005.
61. Kong F, Ying H, Du C, Huang S, Zhou J, Chen J, Sun L, Chen X, Hu C. Patterns of local-regional failure after primary intensity modulated radiotherapy for nasopharyngeal carcinoma. Radiation oncology (London, England). 2014 Feb 19:9():60. doi: 10.1186/1748-717X-9-60.
62. Zhang S, Yang S, Xu P, Xu Y, Zhou G, Ou X, Wu R, Lan M, Fontanarosa D, Dowling J, Wang X, Lin S, Yi JL, Sun Y, Hu C, Lang J. Variations of Clinical Target Volume Delineation for Primary Site of Nasopharyngeal Cancer Among Five Centers in China. Frontiers in oncology. 2020:10():1572. doi: 10.3389/fonc.2020.01572.
63. Buehrlen M, Zwaan CM, Granzen B, Lassay L, Deutz P, Vorwerk P, Staatz G, Gademann G, Christiansen H, Oldenburger F, Tamm M, Mertens R. Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG. Cancer. 2012 Oct 1:118(19):4892-900. doi: 10.1002/cncr.27395.
64. Young T, Thwaites D, Holloway L. Assessment of electron density effects on dose calculation and optimisation accuracy for nasopharynx, for MRI only treatment planning. Australasian physical & engineering sciences in medicine. 2018 Dec:41(4):811-820. doi: 10.1007/s13246-018-0675-2.
65. Bouaouina N, Ouni S, Kanoun SB, Neffeti AB, Kermani W, Abdelkefi M. [Metastatic nasopharynx cancer at diagnosis: clinical and prognostic (study of 51 cases)]. The Pan African medical journal. 2018:29():155. doi: 10.11604/pamj.2018.29.155.11257.
66. Gabani P, Barnes J, Lin AJ, Rudra S, Oppelt P, Adkins D, Rich JT, Zevallos JP, Daly MD, Gay HA, Thorstad WL. Induction chemotherapy in the treatment of nasopharyngeal carcinoma: Clinical outcomes and patterns of care. Cancer medicine. 2018 Aug:7(8):3592-3603. doi: 10.1002/cam4.1626.
67. Chen YP, Ismaila N, Chua MLK, Colevas AD, Haddad R, Huang SH, Wee JTS, Whitley AC, Yi JL, Yom SS, Chan ATC, Hu CS, Lang JY, Le QT, Lee AWM, Lee N, Lin JC, Ma B, Morgan TJ, Shah J, Sun Y, Ma J. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Mar 1:39(7):840-859. doi: 10.1200/JCO.20.03237.

68. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Apr:16(4):1310-7
69. Chan AT, Leung SF, Ngan RK, Teo PM, Lau WH, Kwan WH, Hui EP, Yiu HY, Yeo W, Cheung FY, Yu KH, Chiu KW, Chan DT, Mok TS, Yau S, Yuen KT, Mo FK, Lai MM, Ma BB, Kam MK, Leung TW, Johnson PJ, Choi PH, Zee BC. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. Journal of the National Cancer Institute. 2005 Apr 6:97(7):536-9
70. Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, Chua ET, Yang E, Lee KM, Fong KW, Tan HS, Lee KS, Loong S, Sethi V, Chua EJ, Machin D. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Sep 20:23(27):6730-8
71. Chen Y, Sun Y, Liang SB, Zong JF, Li WF, Chen M, Chen L, Mao YP, Tang LL, Guo Y, Lin AH, Liu MZ, Ma J. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. Cancer. 2013 Jun 15:119(12):2230-8. doi: 10.1002/cncr.28049.
72. Lee AWM, Tung SY, Ng WT, Lee V, Ngan RKC, Choi HCW, Chan LLK, Siu LL, Ng AWY, Leung TW, Yiu HHY, O'Sullivan B, Chappell R. A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. Cancer. 2017 Nov 1:123(21):4147-4157. doi: 10.1002/cncr.30850.
73. Kwong DL, Sham JS, Au GK, Chua DT, Kwong PW, Cheng AC, Wu PM, Law MW, Kwok CC, Yau CC, Wan KY, Chan RT, Choy DD. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Jul 1:22(13):2643
74. Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, Yu BK, Chiu SK, Kwan WH, Ho R, Chan I, Ahuja AT, Zee BC, Chan AT. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 10:27(2):242-9. doi: 10.1200/JCO.2008.18.1545.
75. Lee AW, Ngan RK, Tung SY, Cheng A, Kwong DL, Lu TX, Chan AT, Chan LL, Yiu H, Ng WT, Wong F, Yuen KT, Yau S, Cheung FY, Chan OS, Choi H, Chappell R. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 2015 Apr 15:121(8):1328-38. doi: 10.1002/cncr.29208.
76. Cao SM, Yang Q, Guo L, Mai HQ, Mo HY, Cao KJ, Qian CN, Zhao C, Xiang YQ, Zhang XP, Lin ZX, Li WX, Liu Q, Qiu F, Sun R, Chen QY, Huang PY, Luo DH, Hua YJ, Wu YS, Lv X, Wang L, Xia WX, Tang LQ, Ye YF, Chen MY, Guo X, Hong MH. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. European journal of cancer (Oxford, England : 1990). 2017 Apr:75():14-23. doi: 10.1016/j.ejca.2016.12.039.
77. Yang Q, Cao SM, Guo L, Hua YJ, Huang PY, Zhang XL, Lin M, You R, Zou X, Liu YP, Xie YL, Wang ZQ, Mai HQ, Chen QY, Tang LQ, Mo HY, Cao KJ, Qian CN, Zhao C, Xiang YQ, Zhang XP, Lin ZX, Li WX, Liu Q, Li JB, Ling L, Guo X, Hong MH, Chen MY. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre

randomised controlled trial. European journal of cancer (Oxford, England : 1990). 2019 Sep:119():87-96. doi: 10.1016/j.ejca.2019.07.007.

78. Lee AWM, Ngan RKC, Ng WT, Tung SY, Cheng AAC, Kwong DLW, Lu TX, Chan ATC, Sze HCK, Yiu HHY, Wong FCS, Yuen KT, Chappell R, Choi HCW. NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma. Cancer. 2020 Aug 15:126(16):3674-3688. doi: 10.1002/cncr.32972.
79. Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. The Lancet. Oncology. 2012 Feb:13(2):163-71. doi: 10.1016/S1470-2045(11)70320-5.
80. Chitapanarux I, Kittichest R, Tungkasamit T, Asakit T, Chomprasert K, Chakrabandhu S, Onchan W, Traisathit P. Two-year outcome of concurrent chemoradiation with carboplatin with or without adjuvant carboplatin/fluorouracil in nasopharyngeal cancer: A multicenter randomized trial. Current problems in cancer. 2021 Feb:45(1):100620. doi: 10.1016/j.currproblcancer.2020.100620.
81. Liu K, Wang J. Developing a nomogram model and prognostic analysis of nasopharyngeal squamous cell carcinoma patients: a population-based study. Journal of cancer research and clinical oncology. 2023 Oct:149(13):12165-12175. doi: 10.1007/s00432-023-05120-3.
82. Peng WS, Xing X, Li YJ, Ding JH, Mo M, Xu TT, Zhou X, Hu CS. Prognostic nomograms for nasopharyngeal carcinoma with nodal features and potential indication for N staging system: Validation and comparison of seven N stage schemes. Oral oncology. 2023 Sep:144():106438. doi: 10.1016/j.oraloncology.2023.106438.
83. Alami IE, Gihbid A, Charoute H, Khaali W, Brahim SM, Tawfiq N, Cadi R, Belghmi K, El Mzibri M, Khyatti M. Prognostic value of Epstein-Barr virus DNA load in nasopharyngeal carcinoma: a meta-analysis. The Pan African medical journal. 2022:41():6. doi: 10.11604/pamj.2022.41.6.28946.
84. Wu CF, Lin L, Mao YP, Deng B, Lv JW, Zheng WH, Wen DW, Kou J, Chen FP, Yang XL, Xu SS, Ma J, Zhou GQ, Sun Y. Liquid biopsy posttreatment surveillance in endemic nasopharyngeal carcinoma: a cost-effective strategy to integrate circulating cell-free Epstein-Barr virus DNA. BMC medicine. 2021 Aug 26:19(1):193. doi: 10.1186/s12916-021-02076-4.
85. Thamboo A, Tran KH, Ye AX, Shoucair I, Jabarin B, Prisman E, Garnis C. Surveillance tools for detection of recurrent nasopharyngeal carcinoma: An evidence-based review and recommendations. World journal of otorhinolaryngology - head and neck surgery. 2022 Sep:8(3):187-204. doi: 10.1016/j.wjorl.2020.12.002.
86. Wei J, Pei S, Zhu X. Comparison of 18F-FDG PET/CT, MRI and SPECT in the diagnosis of local residual/recurrent nasopharyngeal carcinoma: A meta-analysis. Oral oncology. 2016 Jan:52():11-7. doi: 10.1016/j.oraloncology.2015.10.010.
87. Ng SH, Chan SC, Yen TC, Liao CT, Chang JT, Ko SF, Wang HM, Lin CY, Chang KP, Lin YC. Comprehensive imaging of residual/ recurrent nasopharyngeal carcinoma using whole-body MRI at 3 T compared with FDG-PET-CT. European radiology. 2010 Sep:20(9):2229-40. doi: 10.1007/s00330-010-1784-9.
88. Liu T, Xu W, Yan WL, Ye M, Bai YR, Huang G. FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2007 Dec:85(3):327-35

**إدارة المستشفى السني متعددة التخصصات لمرضى سرطان البلعوم الأنفي الخاضعين للعلاج الكيميائي-الإشعاعي**

**الملخص:**
**الخلفية :**يُعد سرطان البلعوم الأنفي (NPC) من الأورام الخبيثة ذات الوبائيات المميزة، حيث ينتشر بشكل مرتفع في شرق وجنوب شرق آسيا. ويُعزى حدوثه إلى عوامل متعددة تشمل العدوى بفيروس إبشتاين-بار(EBV) ، والقابلية الوراثية، إضافةً إلى العوامل البيئية مثل استهلاك الأطعمة المحفوظة. كما أن الموقع التشريحي العميق للبلعوم الأنفي وظهور المرض غالباً في مراحل متقدمة يجعلان من إدارته السريرية تحدياً معقداً.

**الهدف :**تهدف هذه المراجعة إلى توحيد المعارف الحالية حول الإدارة متعددة التخصصات لمرضى سرطان البلعوم الأنفي الخاضعين للعلاج الكيميائي-الإشعاعي، من خلال تناول الجوانب الوبائية والفيزيولوجيا المرضية والتشخيص والتدريج، بالإضافة إلى بروتوكولات العلاج والدور الحيوي لفرق الرعاية الصحية المتكاملة.

**الطرق :**أُجريت مراجعة شاملة للأدبيات العلمية، جرى من خلالها تحليل المعلومات المتعلقة بالأساس التشريحي للمرض، والتصنيف النسيجي المرضي (أنواع منظمة الصحة العالمية 1–3)، وطرق التقييم التشخيصي) بما في ذلك التنظير، والتصوير الطبقي المحوريCT ، والتصوير بالرنين المغناطيسيMRI ، والتصوير(PET-CT ، إضافةً إلى استعراض الاستراتيجيات العلاجية المبنية على الأدلة. كما تُبرز المراجعة الدور المحوري للعلاج الكيميائي-الإشعاعي المتزامن، خاصة باستخدام نظم تعتمد على السيسبلاتين وتقنية العلاج الإشعاعي المعدل الشدة (IMRT).

**النتائج :**يعتمد علاج سرطان البلعوم الأنفي الموضعي المتقدم) المرحلتان (II–IV بشكل رئيسي على العلاج غير الجراحي، من خلال العلاج الكيميائي-الإشعاعي المتزامن الذي يحقق تحسناً ملحوظاً في معدلات البقاء. وتتيح تقنية IMRT استهدافاً دقيقاً للورم، مما يحسن السيطرة الموضعية ويقلل من السمية. كما يمكن استخدام العلاج الكيميائي الاستهلالي أو اللاحق (Adjuvant) في الحالات المتقدمة. ويعتمد الإنذار على مرحلة المرض، حيث تتراوح معدلات البقاء لخمس سنوات من نحو 82% للمرحلة الأولى إلى 49% للمرحلة الرابعة. وتترافق الرعاية مع مضاعفات حادة ومتأخرة ناجمة عن العلاج، مثل جفاف الفم(Xerostomia) ، وصعوبة البلع، وفقدان السمع.

**الاستنتاج :**يتطلب تدبير سرطان البلعوم الأنفي نهجاً معقداً قائماً على بروتوكولات واضحة تتمحور حول العلاج الكيميائي-الإشعاعي. وتتحقق أفضل النتائج العلاجية من خلال تنسيق متكامل بين فرق متعددة التخصصات، يشتمل على تدقيق في التدريج المرضي، وتقنيات إشعاع متقدمة، وعلاج جهازي فعال، ورعاية داعمة شاملة لمعالجة الآثار الجانبية وضمان المتابعة الطويلة الأمد.

**الكلمات المفتاحية :**سرطان البلعوم الأنفي، العلاج الكيميائي-الإشعاعي، العلاج الإشعاعي المعدل الشدة، فيروس إبشتاين-بار، الفريق متعدد التخصصات، سرطان الرأس والعنق.